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1. Introduction 
1.1. Acute respiratory distress syndrome 
Acute respiratory distress syndrome (ARDS) is a clinical syndrome which 
develops rapidly and results in respiratory failure. A recently proposed interpretation of 
ARDS, the Berlin definition, includes a value of the PaO2/FiO2 ratio of below  
300 mmHg, acute onset and the presence of bilateral opacities present on chest 
radiographs consistent with pulmonary edema (Ranieri et al., 2012). The disease is 
categorized by the degree of hypoxemia: mild (PaO2/FiO2 ratio between 300 and  
200 mmHg), moderate (PaO2/FiO2 ratio between 200 and 100 mmHg) or severe 
(PaO2/FiO2 ratio below 100 mmHg). Patients with ARDS require urgent admission to 
critical care units for advanced life support and utilize considerable health care 
resources.  
Acute respiratory distress syndrome has multiple etiologies and can develop as a 
result of direct injury to the lungs, such as after viral or bacterial pneumonia, aspiration 
of gastric contents, or smoke or toxic gas inhalation. Alternatively, ARDS can occur 
indirectly during the course of systemic inflammation, such as during sepsis; or after 
trauma or blood transfusion (Ware and Matthay, 2000). The risk of ARDS development 
is higher in patients with pneumonia, severe sepsis, and aspiration of gastric contents, 
hemorrhage or trauma (Matthay and Zemans, 2011). Multi-organ failure is the most 
common cause of death in patients with ARDS (Lipes et al., 2012). The mortality rate of 
ARDS is 27-45% and depends on the severity of disease (Ranieri et al., 2012). Mortality 
risk depends on the nature of the underlying disorder and is higher for patients with 
sepsis, pneumonia or aspiration (Rubenfeld et al., 2005; Eisner et al., 2001). 
Additionally, the risk of death is influenced by age and race, since younger patients have 
lower mortality rates and Afro-Americans or Hispanics have increased risk of death 
when compared to Caucasians (Rubenfeld et al., 2005; Eisner et al., 2001). Currently, 
the therapy for ARDS remains limited to lung-protective mechanical ventilation while 
several pharmacological therapies evaluated have proven to be ineffective.  
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1.1.1. Pathology of acute respiratory distress syndrome 
The alveolar-capillary barrier is the basic functional unit of the lung, formed by 
adjacent layers of the alveolar epithelium, a basement membrane and the microvascular 
endothelium. The integrity of this delicate system is crucial for maintaining liquid 
homeostasis in the lung, leaving the alveolar surface relatively dry and, ultimately, 
allowing effective gas exchange.  
Irrespective of the nature of the primary insult triggering ARDS, specific 
histopathological characteristics are common to all ARDS pathology. Based on 
histological evidence, the progression of ARDS can be divided into three phases, with 
the acute phase being the most immediate, followed first by the proliferative and then 
the fibrotic stages, which together constitute the chronic phase.  
The acute phase persists during the initial seven days after insult to the lung. In 
the acute phase, the alveolar-capillary barrier is destroyed, which causes permeability 
and alveolar flooding. In consequence, pulmonary edema develops, which decreases the 
efficiency of gas exchange, and eventually causes respiratory failure. Cell necrosis, 
inflammation and fibrotic processes, collectively referred to as diffuse alveolar damage, 
are routinely observed and are responsible for loss of alveolar-capillary barrier integrity 
(Ware and Matthay, 2000). The key histopathological features of the acute phase of 
ARDS are demonstrated in Figure 1. 
The majority of patients who survive the acute stage of ARDS enter the 
proliferative phase, which is characterized by the presence of hyperplastic alveolar 
epithelial type II (AETII) cells and fibroblasts. The AETII cells migrate along alveolar 
septa and proliferate in order to reconstitute epithelial integrity (Geiser, 2003). 
Additionally, fibroblasts deposit extracellular matrix proteins which transform the  
intra-alveolar space into fibrous tissue and obliterate the alveolar space (Marshall et al., 
1998).  
The effort of epithelial repair undertaken during the proliferative phase may 
result in complete restoration of lung function. Nevertheless, proper re-epithelialization 
is frequently disturbed and can cause progression into the fibrotic phase of ARDS (Ware 
and Matthay, 2000). In this final stage, the alveolar space is filled with proliferating 
fibroblasts, abnormal amounts of extracellular matrix and new blood vessels, a 
characteristic collectively described as fibrosing alveolitis (Ware, 2006).  
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Figure 1. Comparison of a healthy alveolus to a damaged alveolus in the acute phase of acute 
respiratory distress syndrome. A healthy alveolus (left-hand side) is characterized by the presence of 
intact endothelial and epithelial barriers and balanced regulation of the alveolar fluid volume and 
composition. In the acute respiratory distress syndrome (right-hand side), the integrity of the  
alveolar-capillary barrier is lost, which promotes accumulation of protein-rich edema fluid in the alveoli 
(from Ware and Matthay, 2000). 
 
 
1.1.2. Injury to the alveolar-capillary barrier promotes edema 
formation and persistence in acute respiratory 
distress syndrome  
Damage to the endothelial and epithelial barriers perturbs fluid balance and leads 
to alveolar flooding in the acute phase of ARDS (Ware, 2006). The injury to the 
pulmonary vasculature was documented by Tomashefski et al., who reported substantial 
ultrastructural lesions in the capillary endothelium in patients with ARDS (Tomashefski 
et al., 1983). It appears that granulocyte recruitment in the pulmonary microvasculature 
is responsible for capillary endothelial damage (Looney et al., 2006). Activated, 
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degranulating neutrophils are a source of proteases, proinflammatory cytokines, 
procoagulants and reactive oxygen species, all of which can injure microvascular 
endothelial cells and cause extravasation of protein-rich fluid (Matthay and Zemans, 
2011). However, despite that endothelial dysfunction is evident in ARDS, increased 
vascular permeability is insufficient to facilitate edema formation in presence of a 
morphologically and functionally intact alveolar epithelium, suggesting that injury to the 
endothelium alone is incapable to cause ARDS (Wiener-Kronish et al., 1991). 
The intensity of the injury to the epithelium and edema level correlates with the 
severity of the ARDS and is associated with poor outcome (Ware and Matthay, 2001, 
Matthay and Wiener-Kronish, 1990). Destruction of the epithelial wall results in 
functional impairment of lung function on multiple levels. Since alveolar epithelial cells 
are exceptionally tightly connected, the epithelial barrier is much less permeable 
compared to the microvascular endothelial barrier. Therefore, loss of epithelial wall 
integrity has more severe consequences than the destruction of the endothelial layer, and 
contributes to the accumulation of protein-rich edema fluid in the alveoli to a high 
degree (Wiener-Kronish et al., 1991). An ultrastructural study of epithelial injury in 
ARDS revealed cell vacuolization, cytoplasmic swelling, focal detachment from the 
basement membrane, and necrosis (Ware, 2006, Tomashefski, 2000). Eradication of 
alveolar epithelial type I (AETI) cells results in a reduction of gas exchange surface area 
and delivers a major initial blow to epithelial layer integrity, allowing the influx of 
edema fluid into the alveolar space (Ware and Matthay, 2000). On the contrary, AETII 
cells seem to be more resistant to the initial insult. Additionally, AETII cells proliferate 
and differentiate into AETI cells and are critical for re-epithelization and repair of the 
alveolar epithelium after injury (Geiser, 2003). 
Apart from increased fluid permeability, the destruction of the epithelial layer 
has another fundamental consequence in the form of perturbed lung liquid reabsorption 
in ARDS (Modelska et al., 1999, Laffon et al., 1999). The major force driving water 
movement in the lung is Na
+
 transport from the alveolar lumen across the epithelium via 
the apically-located epithelial sodium channel (ENaC) and the basolaterally-located 
sodium/potassium-exchanging ATPase (Na,K-ATPase) into the interstitium (Matthay et 
al., 2002). The polarized distribution of Na
+
 transporters in the plasma membranes of 
alveolar epithelial cells is essential for vectorial Na
+
 transport and formation of an 
osmotic gradient, which is followed by isoosmotic water reabsorption from the alveoli in 
the process of alveolar fluid clearance (AFC) (Matthay et al., 2002).  
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1.2. Alveolar fluid clearance 
Both AETI and AETII cells express elements of the Na
+
 transporting machinery 
and are able to perform Na
+ 
ion transport and drive AFC (Matthay and Zimmerman, 
2005). The function of ENaC is to passively conduct Na
+
 ions from alveolar space into 
alveolar epithelial cells (Guidot et al., 2006). Four types of subunits, α-ENaC, β-ENaC, 
γ-ENaC and δ-ENaC were found in human lung epithelial cells (Zhao et al., 2012, 
Berthiaume and Matthay, 2007). The role of ENaC is important for lung fluid 
homeostasis, since inhibition of ENaC by amiloride partially prevents Na
+
 uptake by 
AETI cells in vitro and inhibits basal AFC in human and other mammalian lungs 
(Matthay et al., 2002). Furthermore, deletion or diminished expression of the mouse  
α-ENaC gene results in pulmonary edema and causes respiratory distress syndrome 
(Egli et al., 2004, Matthay et al., 2002). The activity of ENaC can be directly modulated 
by cAMP, or indirectly, via regulation of gene expression, by glucocorticoids and 
catecholamines (Berthiaume and Matthay, 2007). Additionally, the cystic fibrosis 
transmembrane conductance regulator (CFTR), a Cl
-
 ion channel expressed in AETI and 
AETII cells, has been also found to be involved in the AFC process (Berthiaume and 
Matthay, 2007).  
The Na,K-ATPase generates an electrochemical gradient across the basolateral 
membrane of AETI and AETII cells by actively pumping K
+
 ions into the cell, and 
extruding Na
+
 ions into the interstitium. An analysis of the Na,K-ATPase pump 
structure revealed the presence of three types of subunits: ATP1A, ATP1B and FXYD 
(also known as α, β and γ proteins, respectively). The structure of Na,K-ATPase is 
illustrated in Figure 2. The ATP1A and ATP1B subunits form the core of the  
Na,K-ATPase, and are indispensable for pump function (Geering, 2008). The ATP1A 
subunit, which has four isoforms (ATP1A1-ATP1A4), is the catalytic unit that 
transports Na
+
 and K
+
 ions and hydrolyzes ATP, which is required for ion-conducting 
activity. Since ATP1A is unable to localize itself into cell membrane, the presence of the 
ATP1B subunit (isoforms ATP1B1-ATP1B3) is critically required for assembly, 
membrane insertion and stability of the Na,K-ATPase complex, and only the  
ATP1A-ATP1B heterodimer can perform pump function (Geering, 2006). Moreover, 
Barquin and colleagues have suggested that ATP1B1 subunit abundance is the rate 
limiting factor for Na,K-ATPase assembly and activity in isolated rat AETII cells and 
the lung (Barquin et al., 1997).  
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Figure 2. Architecture of the Na,K-ATPase. The X-ray crystal structure at 3.5 Å resolution of the 
porcine renal Na,K-ATPase consisting of ATP1A (blue), ATP1B (brown) and FXYD (red) subunits 
(adapted from Morth et al., 2007). 
 
 
 
The activity of the Na,K-ATPase is carefully controlled, and involves direct and 
indirect mechanisms. Direct mechanisms include covalent modifications and allosteric 
structure fine-tuning. The indirect system of regulation includes trafficking  
of the Na,K-ATPase between plasma membrane and endosomal pools, and  
synthesis/degradation rate adjustment (Matthay et al., 2002). Moreover, modulation of 
the expression of Na,K-ATPase-encoding genes by hyperoxia or β-adrenergic, 
glucocorticoid/mineralocorticoid and thyroid systems has also been reported 
(Berthiaume and Matthay, 2007, Matthay et al., 2002). Complex regulation of  
pump-encoding gene transcription and mRNA translation have a persistent effect on  
Na,K-ATPase activity, while dopaminergic and adrenergic stimulation rapidly induce 
Na,K-ATPase phosphorylation and trafficking to the cell membrane (Matthay et al., 
2002). Finally, studies with the Na,K-ATPase inhibitor ouabain in AETII cells, in 
ATP1A 
ATP1B 
FXYD 
Cytoplasm 
Extracellular 
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resected human lungs and in live animals revealed that the Na,K-ATPase is essential for 
Na
+
 transport and AFC in intact healthy lungs as well as after injury (Berthiaume and 
Matthay, 2007, Matthay et al., 2002).  
 
1.2.1. Alveolar fluid clearance is impaired in acute respiratory 
distress syndrome  
A damaged and permeable alveolar epithelium allows rapid water accumulation 
and edema formation which cannot be resolved because of impaired AFC processes 
caused by defective ion transport (Sartori and Matthay, 2002). A number of factors have 
been shown to perturb transepithelial ion transport and, consequently, decrease AFC 
(highlighted in Figure 3). After lung injury, Na
+
 transport via ENaC and the  
Na,K-ATPase can be directly reduced by secondary inflammatory mediators including 
reactive oxygen and nitrogen species (Lecuona et al., 2007, Morty et al., 2007, Matthay 
et al., 2002). Hypoxia, which develops during ARDS, reduces Na
+
 transport in AETII 
cells and impairs the AFC process (Sartori and Matthay, 2002). Various cytokines that 
are involved in the pathogenesis of ARDS, including tumor necrosis factor-α,  
interleukin-1β and transforming growth factor (TGF)-β, and infectious agents, including 
Pseudomonas or influenza virus; inhibit Na
+
 transport and prevent AFC (Morty et al., 
2007, Frank et al., 2003, Matthay et al., 2002, Evans et al., 1998). Additionally, active 
Na
+
 transport and subsequent AFC are inhibited by Na,K-ATPase endocytosis  
early in sepsis-induced lung injury (Berger et al., 2011). Lecuona and colleagues  
described a reduction in Na,K-ATPase function in AETII cells in a rat model of 
ventilator-induced ARDS. Since AFC in these animals was also reduced, this study 
highlights the importance of proper patient ventilation in the intensive care unit, which 
must not further hamper already weakened Na
+
 transport and edema fluid resolution 
mechanisms (Lecuona et al., 1999). Despite the strong evidence for decreased 
transepithelial Na
+
 transport in various models of ARDS, it is important to note that mild 
lung injury can have the opposite effect and improve Na
+
 transport and AFC (Matthay et 
al., 2002). Increased Na
+
 uptake after mild lung injury may serve as a natural 
mechanism preventing alveolar flooding and may offer some protection against lung 
injury.    
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Figure 3. Mechanisms of perturbed alveolar fluid clearance leading to the formation and 
persistence of pulmonary edema after lung injury. TGF-β, transforming growth factor-β; ANF, atrial 
natriuretic factor (from Morty et al., 2007). 
 
 
1.2.2. Upregulation of alveolar fluid clearance can improve 
acute respiratory distress syndrome 
Several clinical studies demonstrate that patients with enhanced AFC display 
improvement in ARDS and increased survival in contrast to those without efficient AFC 
function (Ware and Matthay, 2001, Matthay and Wiener-Kronish, 1990, Ware et al., 
1999). Therefore, it is reasonable to preserve and, if possible, to increase AFC in the 
lungs of ARDS patients (Berthiaume and Matthay, 2007, Sartori and Matthay, 2002). A 
number of experimental studies have demonstrated the positive impact of Na
+
 transport 
reactivation on increased AFC in animal models of ARDS (reviewed by Morty et al., 
2007 and Sartori and Matthay, 2002; summarized in Figure 4). Dopamine and  
β2-agonists have been reported to stimulate AFC in multiple experimental models of 
ARDS by exocytosis of Na,K-ATPase from intracellular pools to the basolateral cell 
membrane of alveolar epithelial cells. The positive effect of β2-agonists on pulmonary 
edema resolution in humans has been reported by Perkins and colleagues, who observed 
decreased lung water in a randomized placebo-controlled clinical phase II trial of 40 
ARDS patients receiving intravenous salbutamol (Perkins et al., 2006). However, 
despite these encouraging results, large, randomized and placebo-controlled clinical trial 
Introduction 
 18 
on 282 patients with ARDS did not demonstrate increased number of ventilator-free 
days in the group receiving aerolized albuterol, while another study of intravenous 
treatment with salbutamol revealed that use of β2-agonists could even worsen outcome 
(Gao Smith et al., 2012, ARDS Network, 2011).  
Several groups have reported that animals or isolated lungs pretreated with 
keratinocyte growth factor (KGF) or KGF-expressing virus particles displayed enhanced 
Na
+
 transport and AFC, and did not develop edema in response to injury (Baba et al., 
2007, Morty et al., 2007). It has been demonstrated that transepithelial ion transport is 
increased in KGF-treated rat AETII cells, which could be attributed to upregulation of 
Atp1a1 gene expression and increased Atp1a1 and Atp1b1 protein abundance in these 
cells (Borok et al., 1998). Similar to KGF, transforming growth factor (TGF)-α also has 
the capability of improving AFC, albeit through increasing Na
+
 uptake as opposed to 
KGF-induced Na,K-ATPase expression (Folkesson et al., 1996). Additionally,  
TGF-α-overexpressing mice demonstrate reduced lung edema and decreased mortality 
in nickel-induced lung injury (Hardie et al., 2002).  
  
 
 
Figure 4. Strategies for improving Na
+
 transport and edema resolution in acute respiratory distress 
syndrome. CFTR, cystic fibrosis transmembrane conductance regulator; EGF, epidermal growth factor 
(from Morty et al., 2007).  
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Contrary to routes of indirect stimulation of Na
+
 transport, gene therapy by the 
delivery of Na,K-ATPase subunit-encoding DNA directly augments Na
+
 transporting 
machinery and improves AFC and edema resolution (Adir et al., 2003, Azzam et al., 
2002, Stern et al., 2000, Factor et al., 2000, Factor et al., 1998). Interestingly, these 
experiments proved that increased AFC in ARDS apparently relies on the ATP1B1 
subunit (responsible for Na,K-ATPase membrane stability), but not on the ATP1A1 
subunit (serving as Na,K-ATPase catalytic centre).  
As mentioned above, indirect stimulation of the Na,K-ATPase by TGF-α and 
KGF, or direct pump augmentation by ATP1B1 subunit overexpression, improved Na
+
 
transport only in a pretreatment setting, thus limiting the therapeutic potential of these 
approaches in established ARDS. Moreover, lung protective ventilation with low tidal 
volumes, the only valid option for ARDS patients, is still not widely employed in 
intensive care units (Lipes et al., 2012, ARDS Network, 2000). This fact, together with 
the recently reported ineffectiveness of β2-agonist therapy, limits possible treatment 
options for ARDS. The lack of effective treatment options, the overall high mortality 
and the significant economic burden of ARDS stress the need for the development of 
new therapeutic strategies. Advances in our understanding of the pathogenesis of this 
disorder have identified several molecular signaling pathways, including the TGF-β 
network, which could be potential targets for the future therapy of ARDS. 
 
1.3. Transforming growth factor-β signaling 
The members of the TGF-β superfamily of peptide growth factors are 
evolutionarily conserved amongst vertebrates and regulate embryonic development and 
organogenesis, wound repair, immune response and hematopoiesis, and control various 
cell functions (Goumans and Mummery, 2000). The deregulation of TGF-β signaling 
has been implicated in several lung diseases, including cancer, pulmonary fibrosis, 
pulmonary arterial hypertension and ARDS (Santibañez et al., 2011, Eickelberg and 
Morty, 2007, Dhainaut et al., 2003). In alveolar epithelial cells, TGF-β inhibits 
proliferation, induces apoptosis and epithelial-to-mesenchymal transition (Yamasaki  
et al., 2008, Willis and Borok, 2007, Zhang et al., 2004,). Secreted in an inactive  
form and subsequently deposited into extracellular matrix, TGF-β is coupled to  
latency-associated peptide and latent TGF-β-binding proteins. The availability of TGF-β 
is tightly controlled and various factors, including proteases (plasmin, matrix 
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metalloproteinases), reactive oxygen species, integrins and shear forces, have been 
reported to activate and release the deposited TGF-β (Munger and Sheppard, 2011). The 
activated TGF-β can be recognized by the cell surface-expressed TGF-β receptor type I 
(TBRI) and type II (TBRII). The TBRI receptors include activin receptor-like kinase 
(ALK)1 and ALK5, while TGF-β receptor 2 (TGFBR2) represents the TBRII family. 
Additionally, auxiliary type III receptors: betaglycan and endoglin, enhance TGF-β 
signaling by presenting ligand to the TBRI and TBRII complexes (Santibañez et al., 
2011). The serine/threonine kinases TBRI/TBRII form the core of the receptor, and 
upon ligand binding undergo heterodimerization and conformational changes in a series 
of phosphorylation events (Massagué and Chen, 2000). Initially, recognition of the 
ligand by TBRII triggers phosphorylation of TBRI followed by reorganization of 
receptor structure and results in tight association of both molecules. In the subsequent 
step, TBRI catalyzes the phosphorylation and activation of SMAD proteins (homologs 
of the Drosophila protein mothers against decapentaplegic (MAD) and Caenorhabditis 
elegans protein SMA) which are docked to the receptor complex on cytoplasmatic side 
(Massagué and Gomis, 2006).  
 
1.3.1. Function of SMAD proteins in the transcriptional 
regulation of gene expression  
In the canonical TGF-β pathway (schematically depicted in Figure 5), activated 
SMAD2 and SMAD3 proteins form complexes with SMAD4, translocate into the 
nucleus and act as transcription factors (Massagué and Chen, 2000). Also called receptor 
SMADs (R-SMADs), SMAD2 and SMAD3 share similar protein structures, with the 
presence of highly conserved MH1 and MH2 (where MH is Mad homology) domains on 
the N-terminus and the C-terminus, respectively, separated by linker region. The MH1 
domain is responsible for DNA binding while MH2 domain express transcriptional 
regulation activity and facilitates protein-protein interactions (ten Dijke and Hill, 2004, 
Ross and Hill, 2008).  
Heterodimers consisting R-SMADs and SMAD4 form multiprotein complexes 
with various transcription factors and transcription co-factors in order to execute the 
primary function of the TGF-β/SMAD signaling which is gene expression regulation 
(Massagué and Chen, 2000). 
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Figure 5. Overview of the TGF-β signaling pathway. CBP, CREB binding protein; CtBP, C-terminal 
binding protein; DNA-BP, DNA-binding protein; HDAC, histone deacetylase; Pol II, RNA polymerase II; 
RI, type I receptor; RII, type II receptor; TFIID, transcription factor II D (adapted from Feng and 
Derynck, 2005). 
 
 
The intrinsic DNA-binding capability of SMADs is relatively weak and it seems 
that these proteins do not exhibit strict DNA sequence specificity by binding  
5-AGAC-3 sequences as well as GC-rich DNA regions, while the most abundant 
SMAD2 isoform completely lacks DNA-binding activity (Shi et al., 1998, Zawel et al., 
1998, Kim et al., 1997). To overcome these drawbacks, SMAD proteins frequently 
recruit other transcription factors to specifically target and regulate genes downstream of 
TGF-β signaling. Additionally, as the TGF-β pathway regulates the expression of more 
than 1300 genes in the human AETII cell-like A549 cell-line alone, these additional 
transcription factors are necessary to aid the structurally similar SMAD proteins in 
precise, dynamic and cell-specific gene regulation (Ranganathan et al., 2007, Keating et 
al., 2006).  
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1.3.2. SMAD-associated transcription factors and 
transcription co-factors 
A significant number of transcription factors interact and regulate gene 
expression in concert with SMADs (Feng and Derynck, 2005). The character of the 
partner transcription factor governs the response to TGF-β and may result in the 
upregulation or downregulation of target gene expression. The DNA-binding 
transcription factors known to form transcription-activating complexes with SMADs 
include forkhead box protein O (FoxO) proteins, specificity protein 1 (Sp1), 
transcription factor E3 (TFE3) and basic leucine zipper (bZIP) family proteins c-Jun, 
JunB or activating transcription factor (ATF) 2 and ATF3 (Feng and Derynck, 2005, 
Seoane et al., 2004, Feng et al., 2000, Hua et al., 1999). Additionally, TGF-β signaling 
synergizes with NF-kappaB, Notch and p53 pathways (Blokzijl et al., 2003, Cordenonsi 
et al., 2003, López-Rovira et al., 2000). The primary role of SMADs and partner 
transcription factors is recognition and binding to specific DNA sequences in the TGF-β 
target gene promoter. However, the capacity of SMAD proteins to induce transcription 
is limited, and additional factors, named transcriptional co-activators, are required. The 
transcriptional co-activators (such as switch/sucrose nonfermentable (SWI/SNF) and 
ARC105 proteins) lack intrinsic DNA-binding domains but have the ability to modify 
chromatin structure and stabilize transcriptional machinery, thus significantly 
amplifying the rate of transcription (Ross et al., 2006, Massagué et al., 2005, Kato et al., 
2002).  
In contrast to driving gene expression, the mechanisms of TGF-β-dependent 
gene repression are much less understood, and a number of SMAD-associated 
transcription factors can play a dual role, acting as a activators as well as repressors, 
including the already-mentioned p53 (Cordenonsi et al., 2003, Wilkinson et al., 2005). 
Up to now, several mechanisms of TGF-β/SMAD-regulated gene repression have been 
described. The gene-activating function of SMADs can be directly suppressed by 
binding ecotropic virus integration site 1 protein homolog (EVI-1), yin-yang 1 (YY1), 
Sloan-Kettering institute (SKI) and Ski-related novel protein N (SnoN) transcriptional 
repressors (Kurisaki et al., 2003, Alliston et al., 2005). Conversely, SMADs may abolish 
the function of transcriptional activators, as in the case of the interaction between 
SMAD3 and Runt-related transcription factor 2 (RUNX2) (Alliston et al., 2001). 
Finally, SMADs may form complexes with specialized transcriptional repressors E2F4 
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and E2F5 to inhibit gene expression (Chen et al., 2002). Several other transcriptional 
regulators including transforming growth interacting factor (TGIF), SKI and SNON, can 
associate with SMADs and may repress the gene expression in a similar fashion 
(Liberati et al., 2001, Stegmüller et al., 2008, Mizuide et al., 2003, Stroschein  
et al., 1999, Wotton et al., 1999). Likewise, transcription factor ATF3 associates with 
SMAD3 in TGF-β-treated epithelial cells and represses the ID1 gene (Kang et al., 
2003). Finally, Vincent and colleagues reported that TGF-β-induces the interaction 
of SMAD3 and SMAD4 with the transcriptional repressor SNAI1, leading to  
repression of CAR, OCCLUDIN, CLAUDIN-3 and E-CADHERIN genes and ultimately  
epithelial-to-mesenchymal transition (Vincent et al., 2009).  
 
1.3.3. Epigenetic mechanisms in TGF-β-dependent gene 
regulation  
While binding DNA, SMADs and associated transcription factors recruit 
transcriptional co-activators or co-repressors to finally execute a gene activation or 
repression program. These two opposite processes may involve epigenetic mechanisms, 
which modify the accessibility of the eukaryotic transcription machinery by methylating 
DNA, or by covalently modifying histone proteins. The balance of cytosine methylation 
in 5-CG-3 dinucleotides by DNA methyltransferases and DNA glycosylases is an 
important mechanism of gene regulation during development. Aberrant DNA 
methylation patterns have been identified in several diseases including cancer (Wu and 
Grunstein, 2000). Histone proteins form the core of the nucleosome, the basic structural 
unit of chromatin, and are responsible for chromatin compacting. Histones are subjected 
to extensive posttranslational modifications, including lysine acetylation, lysine and 
arginine methylation, and serine, threonine or tyrosine phosphorylation (Wu and 
Grunstein, 2000). These covalent modifications alter the histone-DNA interaction and 
may allow transcription by opening the chromatin structure or facilitate the formation of 
a closed state of chromatin, which is inaccessible to the transcription machinery. Lysine 
acetylation plays an important role during the regulation of gene expression, and this 
modification is characteristic of genes undergoing active transcription. Two types of 
transcription co-factors control lysine acetylation and, therefore, gene expression: 
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histone acetyltransferase (HAT) activates while histone deacetylase (HDAC) represses 
transcription (Wu and Grunstein, 2000).  
TGF-β signaling utilizes the function of DNA glycosylases, HAT and HDAC 
proteins to regulate gene expression. Thillainadesan and colleagues demonstrated that 
TGF-β induces the interaction between SMAD2-SMAD3 and thymine DNA 
glycosylase, which conducts active DNA demethylation, activating the p15
ink4b
 gene 
(Thillainadesan et al., 2012). Several SMAD-interacting proteins exhibit endogenous 
HAT activity. A study by Kahata and colleagues revealed that a histone H3 
acetyltransferase, GCN5, together with SMAD3, localize to the SERPINE1 gene 
promoter and activate transcription (Kahata et al., 2004). Moreover, SMAD3, together 
with SMAD2, forms a complex with another HAT enzyme, p300/CBP-associated factor 
(PCAF), which amplifies the transcription-inducing properties of SMADs (Kahata et al., 
2004, Itoh et al., 2000). Undoubtedly, the nature of the interaction between p300/CBP 
and SMAD2, SMAD3 and SMAD4 is the most well documented among all  
SMAD-interacting HATs (Nishihara et al., 1998, Pouponnot et al., 1998). Several  
TGF-β target genes have been identified to be activated by assembled  
p300/CBP-SMAD3 or p300/CBP-SMAD4 complexes, including SERPINE1, p15 and 
the α-2 type I collagen-encoding gene (COL1A2) (Ghosh et al., 2000, Shen et al., 1998, 
Feng et al., 1998).  
The HDAC family forms a distinct group of co-repressors operated by TGF-β 
signaling to downregulate gene expression. Based on homology and cellular 
localization, this family of zinc-dependent hydrolases is separated into four classes: 
class I (HDAC1, HDAC2, HDAC3 and HDAC8), class IIa (HDAC4, HDAC5, HDAC7 
and HDAC9), class IIb (HDAC6 and HDAC10) and class IV (HDAC11) (Bieliauskas 
and Pflum, 2008). It has been reported that SMAD3 and SMAD4 directly interact with 
HDAC1, and protein complexes containing SMADs exhibit histone deacetylation 
activity (Liberati et al., 2001). The interaction of SMAD3 with HDAC4 and HDAC5 
results in repression of the osteocalcin gene (Kang et al., 2005). The recruitment of 
HDAC proteins by SMADs may also be indirect, where other transcription factors serve 
as adaptors. Evidence provided by Wotton and colleagues demonstrated that TGIF 
competes with the p300/CBP activator for binding SMAD2, and recruits HDAC1 to the 
SMAD2-TGIF complex (Wotton et al., 1999). Additionally, SKI and SNON  
co-repressors seem to recruit HDAC proteins to SMAD-containing complexes. Akiyoshi 
et al. demonstrated that SKI abolishes interaction between SMAD3 and p300 HAT and 
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recruits HDAC1 to SMAD3 in TGF-β-stimulated cells (Akiyoshi et al.,  
1999). While SKI-mediated sequestration of HDAC seems to actively antagonize  
TGF-β/SMAD-mediated induction of at least some genes, SNON maintains the TGF-β 
target genes in an inactive state under basal conditions. It has been speculated that 
SNON may recruit HDACs to the SMAD2/SMAD4 complexes via the nuclear receptor 
co-repressor 1 (N-CoR) adaptor protein (Stroschein et al., 1999). The human homolog 
of Drosophila gene Sna, SNAI1, represents another transcription factor known to 
mediate TGF-β signaling, which has also been found to interact with HDACs. Peinado 
and collaborators described a mechanism where SNAI1, together with HDAC1 and 
HDAC2, repress E-Cadherin gene (Peinado et al., 2004). 
 
1.4. The role of TGF-β signaling in acute respiratory distress 
syndrome 
In the lung, TGF-β is secreted by alveolar macrophages, alveolar epithelial cells 
and fibroblasts, and is involved in normal lung tissue repair as well as being a critical 
mediator of pulmonary fibrosis (Khalil et al., 1996, Sime et al., 1997). Additionally, 
several lines of evidence have implicated TGF-β in processes preceding the 
development of pulmonary fibrosis. Increased levels of TGF-β have been found in 
broncho-alveolar lavage (BAL) fluid from ARDS patients and lower levels of TGF-β are 
related to a lower severity of ARDS (Fahy et al., 2003, Budinger et al., 2005). In ARDS, 
TGF-β is expressed by fibroblasts, alveolar macrophages and alveolar epithelial cells 
adjacent to fibrotic foci (Fahy et al., 2003).  
The increased levels of TGF-β in BAL fluids from ARDS patients robustly 
stimulated the activity of the procollagen gene promoter, a fibroproliferative marker and 
predictor of the severity of ARDS, which could indicate that TGF-β may execute gene 
regulation programs shortly after the onset of lung injury (Budinger et al., 2005). An 
analysis of gene expression dynamics in bleomycin- or nickel-induced ARDS models 
identified a group of TGF-β-target genes involved in the inflammatory response and 
extracellular matrix deposition to be differentially regulated shortly after the onset of 
injury. Additionally, the expression of the β-ENaC subunit- and Na,K-ATPase Atp1b1 
subunit-encoding genes was decreased, suggesting that disruption of the AFC machinery 
may occur very early during ARDS progression (Wesselkamper et al., 2005). In vitro 
experiments confirmed that TGF-β boosts vascular endothelial cell permeability, and 
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decreases transepithelial electrical resistance of primary AETII cells, suggesting a key 
role for TGF-β signaling in the regulation of ion transport and pulmonary edema 
formation and persistence in ARDS (Pittet et al., 2001, Hurst et al., 1999). It appears 
that TGF-β directly targets ENaC channels to perturb ion transport in the lung, as TGF-β 
treatment decreases α-ENaC subunit-encoding gene expression, and inhibits  
amiloride-sensitive Na
+
 uptake and fluid transport across the alveolar epithelium in vitro 
and in vivo (Frank et al., 2003). In contrast, low doses of TGF-β not only preserve  
α-ENaC subunit encoding gene expression but also increase the abundance of  
Na,K-ATPase subunits ATP1A1 and ATP1B1, and stimulate active ion transport across 
AETII cell monolayers (Willis et al., 2003). It is important to note, however, that this 
effect was accompanied by reduced transepithelial resistance and perturbed formation of 
tight epithelial monolayers (Willis et al., 2003). Collectively, these observations imply 
that TGF-β may have a biphasic effect on the epithelial barrier, by stimulating active ion 
transport at low doses, and disrupting barrier integrity at higher concentrations.  
Additional evidence confirming the involvement of TGF-β in ARDS comes from 
studies where investigators employed tools to block the TGF-β signaling in animal 
models of ARDS. Pittet and colleagues have suggested a key role of integrin αvβ6 in the 
local activation of latent TGF-β, since αvβ6-/- mice are protected from edema formation, 
hemorrhage and accumulation of proteinaceous material in the alveoli after bleomycin 
or endotoxin instillation (Pittet et al., 2001). Additionally, scavenging active TGF-β with 
a soluble chimeric TGF-β type II receptor decreases protein levels in BAL fluid and 
epithelial permeability to protein in nickel- and bleomycin-induced lung injury (Pittet et 
al., 2001, Wesselkamper et al., 2005). However, it is important to note that blocking 
TGF-β signaling does not affect neutrophil recruitment to the alveoli, suggesting that 
neutrophil-mediated inflammatory responses are not modulated by TGF-β 
(Wesselkamper et al., 2005).  
Despite the evident involvement of TGF-β in ARDS pathogenesis, functional 
TGF-β signaling is an important mechanism ensuring organ homeostasis and lung 
recovery from ARDS. Both inflammation and extracellular matrix modulation are 
engaged in the tissue repair processes, and are dynamically regulated by TGF-β. In this 
way, locally deposited TGF-β may be activated by proximal damage and, in response, 
coordinate securing the perimeter around injured lung tissue and limit the potentially 
dangerous uncontrolled spread of inflammation (Sheppard, 2006). 
Hypothesis and aims of the study 
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2. Hypothesis and aims of the study 
The formation and persistence of pulmonary edema is a hallmark of ARDS 
(Ranieri et al., 2012). The resolution of pulmonary edema in ARDS is inhibited by 
impaired Na
+
 transport and insufficient AFC (Sartori and Matthay, 2002). The 
basolaterally-located Na,K-ATPase establishes an electrochemical gradient across the 
epithelium which drives osmotic water reabsorption from the alveoli (Matthay et al., 
2002). The expression of genes encoding the essential Na,K-ATPase subunit, Atp1b1, 
has been reported to be reduced in a nickel-induced ARDS model (Wesselkamper et al., 
2005). Furthermore, TGF-β has been recognized as a key mediator of ARDS 
pathogenesis, and is known to perturb Na
+
 transport and AFC (Wesselkamper et al., 
2005, Pittet et al., 2001, Massagué and Chen, 2000). Therefore, it has been hypothesized 
here that: (i) the expression of Na,K-ATPase encoding genes is deregulated by TGF-β in 
ARDS patients and in bleomycin model of ARDS in mice; and (ii) restoration of normal 
expression of genes encoding Na,K-ATPase subunits may improve AFC in the 
bleomycin model of ARDS.  
 
In detail, the specific aims of this study were: 
1. to investigate whether parallel trends in the expression of the Na,K-ATPase 
subunit-encoding genes exist in the lungs from ARDS patients and in alveolar 
epithelial cells treated with TGF-β; 
2. to elucidate the mechanism of TGF-β-induced regulation of Na,K-ATPase 
subunit-encoding genes simultaneously regulated in ARDS patients and  
TGF-β-treated cells; 
3. to target and disrupt the gene expression regulatory machinery employed by 
TGF-β signaling to regulate the Na,K-ATPase subunit-encoding gene 
expression; 
4. to test whether recuperation of the Na,K-ATPase subunit-encoding gene 
expression may improve alveolar edema status in the bleomycin model of 
ARDS. 
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3. Materials and methods 
3.1. Materials 
3.1.1. Technical equipment 
Autoclave; Systec, Germany 
Bacteria culture incubator; Heraeus, Germany 
Cell culture incubator HERAcell 150i; Thermo Scientific, USA 
Cell culture sterile working bench; Thermo Scientific, USA 
Cell strainers: 100, 40 μm; BD Falcon™, USA 
Centro LB 960 microplate luminometer; Berthold, Germany 
Costar
®
 12 mm Snapwell™ insert; Corning, USA 
Countess
®
 cell counter; Invitrogen, UK 
Developing machine X Omat 2000; Kodak, USA 
Dynal
®
 MX2 sample mixer; Applied Biosystems, USA 
Electrophoresis chambers; Bio-Rad, USA 
Espresso personal microcentrifuge; VWR, USA 
Gel blotting paper; Bioscience, Germany 
InoLab
®
 pH meter; WTW, Germany 
Isoplate™ B&W 96-well plate; PerkinElmer, USA 
Light microscope; Leica, Germany 
MicroAmp
®
 8-tube strip; Applied Biosystems, USA 
MicroAmp
®
 FAST 96-well reaction plate; Applied Biosystems, USA 
Microcentrifuge tubes: 0.5, 1.5, 2 ml; Eppendorf, Germany 
Microsprayer™; Penn-Century Inc, USA 
Mini shaker; VWR, USA 
Mini Trans-Blot
® 
western blot chambers; Bio-Rad, USA 
Mini-Protean
®
 3 Cell; Bio-Rad, USA 
Minispin
®
 centrifuge; Eppendorf, Germany 
Multifuge 3 S-R centrifuge; Heraeus, Germany 
MS-100 thermo shaker; Universal Labortechnik, Germany 
NanoDrop
®
 ND 1000; PeqLab, Germany 
Nylon net filters 20 μm; Millipore, USA 
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peqSTAR 96 universal gradient thermocycler; Peqlab, USA 
Petri dishes for bacteria; Greiner Bio-One, Germany 
Pipetboy; Eppendorf, Germany 
Pipetmans: P10, P20, P100, P200, P1000; Gilson, France 
Pipetman filter tips: 10, 20, 100, 200 and 1000 μl; Greiner Bio-One, Germany 
Precellys
®
 24 homogenizer; Bertin Technologies, France  
Refrigerated microcentrifuge CT15RE; VWR, USA 
Serological pipettes: 2, 5, 10, 25, 50 ml; Falcon, USA 
Sonopuls HD 2070 ultrasonic homogenizer; Bandelin, Germany 
StepOnePlus™ Real-Time PCR system; Applied Biosystems, USA 
Test tubes: 15, 50 ml; Greiner Bio-One, Germany 
Tissue culture dish 100 mm; Greiner Bio-One, Germany 
Tissue culture flask 250 ml; Greiner Bio-One, Germany 
Tissue culture plates: 6-, 12-, 48- and 96-well; Greiner Bio-One, Germany 
Tissue culture plates: 12-well; Greiner Bio-One, Germany 
Tissue culture plates: 48-well; Greiner Bio-One, Germany 
Tissue culture plates: 96-well; Greiner Bio-One, Germany 
Transfer membrane nitrocellulose; Bio-Rad, USA 
Vasofix
®
 Safety intravenous catheter; B. Braun, Germany 
VersaMax micro-plate reader; Molecular Devices, USA 
Vortex mixer; VWR, USA 
 
3.1.2. Chemicals and reagents 
2-Propanol; Merck, Germany 
5-Aza-2′deoxycytidine; Sigma-Aldrich, Germany  
Agarose; Promega, Germany 
Agarose, low melting point; Sigma-Aldrich, Germany   
Anti-CD16/32 antibody; BD Biosciences, USA 
Anti-CD31 antibody; BD Biosciences, USA 
Anti-CD45 antibody; BD Biosciences, USA 
Anti-HDAC2 antibody (chromatin immunoprecipitation); Pierce Biotechnology, USA 
Ammonium chloride; Sigma-Aldrich, Germany 
Ammonium persulfate; Promega, Germany 
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Ampicillin sodium salt; Sigma-Aldrich, Germany 
Bovine serum albumin; Sigma-Aldrich, Germany 
Bromophenol blue; Sigma-Aldrich, Germany 
Calcium chloride; Sigma-Aldrich, Germany 
Complete™ protease inhibitor; Roche, Germany 
Deoxycholate; Sigma-Aldrich, Germany 
Dispase; BD Biosciences, USA 
3,3′-Dithiodipropionic acid di(N-hydroxysuccinimide ester); Sigma-Aldrich, Germany 
DMSO; Sigma-Aldrich, Germany 
DNase I; Serva, Germany 
dNTP mix; Promega, USA 
DTT; Promega, USA 
Dual-Luciferase
®
 reporter assay system; Promega, USA 
Dulbecco’s modiﬁed Eagle's medium; Gibco BRL, Germany 
Dulbecco’s modiﬁed Eagle's medium, high glucose; Gibco BRL, Germany 
Dulbecco’s phosphate buffered saline, 10×; PAA Laboratories, Austria 
Dulbecco’s phosphate buffered saline, 1×; PAA Laboratories, Austria 
Dynabeads
®
, streptavidin-coupled; Invitrogen, UK 
EDTA; Sigma-Aldrich, Germany  
EGTA; Sigma-Aldrich, Germany  
Ethanol 70%; SAV-LP, Germany 
Ethanol 99%; J.T. Baker Mallinckrodt Baker B.V., Netherlands 
Ethanol absolute; Riedel-de Haën, Germany 
Ethidium bromide; Promega, USA 
Evans blue; Sigma-Aldrich, Germany  
Fetal calf serum; PAA Laboratories, Austria 
Formaldehyde, 37%; Sigma-Aldrich, Germany  
Formamide; Fluka, Germany 
Giemsa’s azur eosin methylene blue solution; Merck, Germany 
Glycerol; Carl Roth, Germany 
Glycine; Carl Roth, Germany 
Hank’s balanced salt solution; PAA Laboratories, Austria  
HEPES; PAA Laboratories, Austria  
HindIII restriction enzyme; Promega, USA 
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Hydrochloric acid; Sigma-Aldrich, Germany 
Igepal
®
 CA-630; Sigma-Aldrich, Germany 
Isoflurane; CP-Pharma, Germany 
Ketamine; Pharmacia & Upjohn, Sweden 
Lipofectamine™ 2000; Invitrogen, UK 
Lithium chloride; Sigma-Aldrich, Germany 
Luria-Bertani medium; Invitrogen, UK 
Magnesium chloride; Sigma-Aldrich, Germany 
Magnesium chloride, 25 mM; Applied Biosystems, USA 
May-Grünwald’s eosin-methylene blue solution; Merck, Germany  
MC1568; Sigma-Aldrich, Germany 
β-Mercaptoethanol; Sigma-Aldrich, Germany 
Methanol; Fluka, Germany 
MGCD0103; Selleck Chemicals, USA  
MuLV reverse transcriptase; Applied Biosystems, USA 
Non-fat dry milk; Carl Roth, Germany 
Normal rabbit IgG; Santa Cruz Biotechnology, USA 
NucleoBond
® 
Xtra midi plasmid midiprep kit; Macherery-Nagel, Germany 
NucleoSpin
®
 RNA II kit; Macherery-Nagel, Germany  
Nuclease-free water; Ambion, USA 
Opti-MEM
®
 medium; Gibco BRL, Germany 
Passive lysis buffer; Promega, USA 
PCR buffer II, 10×; Applied Biosystems, USA 
Penicillin/streptomycin solution; PAA Laboratories, Austria  
pGL3-Basic; Promega, USA 
Platinum
®
 SYBR
®
 Green qPCR SuperMix UDG kit; Invitrogen, USA 
Pierce
®
 BCA protein assay kit; Thermo Scientific, USA 
Potassium bicarbonate; Sigma-Aldrich, Germany 
Precision Plus Protein™ standards; Bio-Rad, USA 
pRL-SV40; Promega, USA 
Protein A/G PLUS-agarose; Santa Cruz Biotechnology, USA 
Proteinase K; Promega, USA 
QIAquick gel extraction kit; Qiagen, Netherlands 
QIAquick PCR purification kit; Qiagen, Netherlands 
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Quick Start™ Bradford dye reagent; Bio-Rad, USA 
Random hexamers; Applied Biosystems, USA 
RIPA buffer; Thermo Scientific, USA 
RNase inhibitor; Applied Biosystems, USA 
Rompun
®
; Bayer, Germany 
Rotiphorese Gel 30 acrylamide/bisacrylamide mixture; Carl Roth, Germany 
SacI restriction enzyme; Promega, USA 
SB431542; Calbiochem, USA 
SDS, 10% solution; Promega, USA 
SDS, powder; Carl Roth, Germany 
Select agar; Sigma-Aldrich, Germany  
Sonicated salmon sperm DNA; Agilent, USA  
Sodium acetate; Sigma-Aldrich, Germany 
Sodium bicarbonate; Sigma-Aldrich, Germany 
Sodium chloride; Merck, Germany 
Sodium orthovanadate; Sigma-Aldrich, Germany 
Sodium phosphate; Sigma-Aldrich, Germany 
Sodium sulfate; Merck, Germany 
SuperSignal
®
 West Femto chemiluminescent substrate; Thermo Scientific, USA 
TEMED; Bio-Rad, USA 
TGF-β1; R&D Systems, USA 
Trichostatin A; Sigma-Aldrich, Germany 
Tris; Carl Roth, Germany 
Triton X-100; Promega, USA 
TRIzol
®
 reagent; Ambion, USA 
Trypan blue; Fluka, Germany 
Trypsin/EDTA; Gibco BRL, Germany 
Tween
®
 20; Sigma-Aldrich, Germany 
 
3.1.3. Cell lines 
A549 epithelial cell line, human lung adenocarcinoma; ATCC-LGC, Germany 
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3.2. Methods 
3.2.1. Human lung material 
All investigations involving human material were approved by the University of 
Giessen Ethics Committee (approval number 29/01). Lung tissue was collected  
at autopsy from five ARDS patients, and from four patients who died of  
myocardial infarction, with no signs of pulmonary disease. Patients with ARDS met all  
American-European consensus conference on ARDS clinical criteria and required 
mechanical ventilation for a mean duration of 92 h. The clinical characteristics of these 
patients are presented in Table 1.  
 
Table 1. The clinical characteristics of acute respiratory distress syndrome 
patients. 
Patient Age Sex Background Modified APACHE II PaO2/FiO2 (mmHg) 
1 40 female Pneumonia 11 83.0 
2 51 female Trauma 6 181.5 
3 48 female Pancreatitis 20 127.2 
4 59 female Trauma 16 137.1 
5 67 male Sepsis 20 109.0 
 
Abbreviations: APACHE, acute physiology and chronic health evaluation; FiO2, 
fraction of inspired oxygen; PaO2, partial pressure of oxygen in arterial blood. 
 
3.2.2. ATP1B1 promoter cloning 
 
3.2.2.1. Sub-cloning of the ATP1B1 promoter from the pGEM-T Easy 
vector into the pGL3-Basic vector 
The pGEM-T Easy-ATP1B1-promoter plasmid containing a 1837-base-pair  
(bp) fragment of the ATP1B1 gene promoter (-3075 to -1238 bp upstream from  
transcription start site) was created by Verena Arnoldt. In order to clone the ATP1B1  
promoter into the firefly luciferase reporter vector pGL3-Basic, 0.2 μg of the  
pGEM-T Easy-ATP1B1-promoter plasmid was digested with HindIII and SacI 
restriction enzymes (6 units of each enzyme was used per reaction) for 1 h at 37 °C. 
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Products of restriction were then analyzed on a 1.5% agarose gel containing 0.5 μg 
ethidium bromide. A single band migrating at approximately 1800 bp corresponding to 
the ATP1B1 promoter was then excised with a clean scalpel and purified using a 
QIAquick gel extraction kit according to the manufacturer instructions. Next, 100 ng of 
the ATP1B1 promoter DNA was mixed with 50 ng pGL3-Basic vector (previously 
digested with HindIII and SacI restriction enzymes) and ligated using T4 DNA Ligase at 
4 °C overnight, thereby creating the pGL3-Basic-ATP1B1-promoter construct.  
 
3.2.2.2. Plasmid transformation of competent cells 
The XL1-Blue competent bacteria cells were transformed using a heat shock 
transformation protocol. Bacterial suspension (50 μl) was transferred into a 1.5 ml tube 
containing 2 μl of the ligation mixture (30 ng of DNA) and incubated for 20 min on ice. 
Next, bacteria were subjected to heat shock at 42 °C for 45 s and the tube was 
immediately transferred back to ice for 2 min. Then, 950 μl of Luria-Bertani medium 
(LB-medium) was added, and the tube was incubated at 37 °C for 1.5 h with shaking at  
150 revolutions per minute (rpm). Thereafter, tubes were centrifuged at 3000 rpm for  
5 min at room temperature (RT), after which, the supernatant was discarded and the 
bacterial pellet was resuspended in 100 μl of LB-medium. The bacterial suspension was 
then plated on LB-agar supplemented with 50 µg/ml ampicillin and incubated at 37 °C 
overnight.  
 
3.2.2.3. Plasmid midi-preparation 
A single bacteria colony was inoculated into 5 ml of LB-medium supplemented 
with 50 µg/ml ampicillin, and incubated for 8 h at 37 °C with shaking at 180 rpm. 
Thereafter, 2 ml of the bacterial pre-culture was transferred into an Ehrlenmeyer flask 
containing 200 ml of LB-medium supplemented with 50 µg/ml ampicillin and incubated 
overnight at 37 °C with shaking at 180 rpm. The pGL3-Basic-ATP1B1-promoter 
plasmid was then extracted from the bacteria culture using a NucleoBond
®
 Xtra Midi kit 
according to the manufacturer’s instructions. 
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3.2.3. A549 cell culture  
The human lung adenocarcinoma epithelial cell line A549 was cultured in tissue 
culture flasks in Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented with 
10% fetal calf serum (FCS) at 37 °C, 5% CO2 and 95-100% humidity. After 80-90% 
confluence was reached, cells were subcultured using a single wash with phosphate 
buffered saline (PBS) followed by incubation with 3 ml Trypsin-EDTA solution for  
3 min at 37 °C. The trypsin activity was inhibited with 7 ml of DMEM containing 10% 
FCS. Next, the cell suspension was diluted 1:5 with DMEM medium supplemented with 
10% FCS and transferred into the fresh tissue culture flask.  
 
3.2.3.1. Treatment of A549 cells  
The A549 cells were treated with 0, 2, 6 or 10 ng/ml TGF-β1 for 1, 2, 3, 24 or  
48 h. Inhibition of TGF-β signaling pathway was achieved by use of SB431542 (20 μM) 
added to the media 1 h before TGF-β1 treatment. Inhibition of DNA methylation was 
achieved by use of 0.1 μM or 10 μM 5-Aza-2′deoxycytidine (5-Aza-2′-dC) added to the 
media 24 h before beginning of TGF-β1 stimulation, and replenished every 24 h over the 
duration of the experiment. Trichostatin A (TSA, 64 nM), MGCD0103 (10 μM) and 
MC1568 (10 or 20 μM) histone deacetylase inhibitors were added 24 h after TGF-β1 
was introduced and were left for another 24 h. 
 
3.2.3.2. Transient transfection of short interfering RNA 
The Lipofectamine™ 2000 transfection reagent was used to transiently transfect 
A549 cells with siRNA. Cells were seeded one day prior transfection into a 12-well 
plate, and were 40-50% confluent at the time of transfection. In order to transfect the 
cells with 100 nM siRNA, 2 μl of Lipofectamine™ 2000 regent was added to 50 μl of 
Opti-MEM
®
 serum-free medium and left for 5 h at RT. Next, siRNA oligonucleotides 
(listed in Table 2) dissolved in Opti-MEM
®
 medium were added, and incubated for  
20 min at RT. For transfection of cells with 200 nM siRNA, 4 μl of Lipofectamine™ 
2000 regent was used. The transfection mixture was then added to the cells cultured in 
the DMEM medium supplemented with 10% FCS. Cells were cultured for 24, 48, 72 or 
96 h under normal cell culture conditions or exposed to 10 ng/ml TGF-β1 after 24 or  
48 h for additional 48 h.  
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Table 2. List of siRNA oligonucleotides used in knock-down experiments. 
Target gene Company Catalog number 
E2F4 Santa Cruz Biotechnology, USA sc-29300 
E2F5 Santa Cruz Biotechnology, USA sc-35250 
HDAC1 Invitrogen, USA 1299001/HSS104725 
HDAC2 Invitrogen, USA 1299001/HSS104728 
HDAC3 Santa Cruz Biotechnology, USA sc-35538 
RUNX2 Qiagen, Netherlands SI00063000 
scrambled siRNA Ambion, USA AM4611 
SMAD2 Santa Cruz Biotechnology, USA sc-44338 
SMAD3 Santa Cruz Biotechnology, USA sc-38376 
SMAD4 Santa Cruz Biotechnology, USA sc-29484 
SNAI1 Santa Cruz Biotechnology, USA sc-38398 
SNON Santa Cruz Biotechnology, USA sc-36518 
YY1 Santa Cruz Biotechnology, USA sc-36863 
 
 
3.2.3.3. Transient transfection of DNA 
The A549 cells were transiently transfected with DNA using Lipofectamine™ 
2000 transfection reagent. Cells were seeded into a 48-well plate and incubated until a 
confluence of 50% was achieved. To transfect the cells, 0.75 μl of Lipofectamine™ 
2000 regent was mixed with 49.25 μl of Opti-MEM® serum-free medium and left for  
5 min at RT. This mixture was then combined with solution containing 300 ng of  
pGL3-Basic-ATP1B1-promoter firefly luciferase reporter combined with 7 ng of  
pRL-SV40 Renilla luciferase co-reporter plasmid in 48.2 μl of Opti-MEM® medium and 
incubated for 20 min. Thereafter, culture medium was exchanged with transfection 
mixture and cells were left for 5 h. Next, transfection medium was aspirated, fresh 
DMEM medium supplemented with 10% FCS was added, and cells were left for 48 h 
under normal cell culture conditions, or treated with 0, 2, 6 or 10 ng/ml TGF-β1. When 
histone deacetylation was studied, 64 nM TSA, 10 μM MGCD0103 or 10 μM MC1568 
inhibitors were added 24 h after TGF-β1 was introduced. In the case of DNA 
methylation inhibition, 0.1 or 10 μM 5-Aza-2′-dC was added 24 h before transfection, 
and was reintroduced every 24 h.  
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3.2.4. Culture of primary mouse alveolar epithelial type II 
cells 
3.2.4.1. Isolation of primary mouse alveolar epithelial type II cells 
Primary AETII cells were isolated using the modified protocol published by 
Corti and collaborators (Corti et al., 1996). Adult male C57BL/6J mice were 
anesthetized with isoflurane. The abdomen was opened by midline incision and mice 
were exsanguinated by transection of the Arteria renalis. The diaphragm was then 
punctured, and after the lung was retracted, the chest was opened and the ribs were fixed 
laterally. The left atrium was then punctured and the lungs were perfused with Hank’s 
balanced salt solution via the right ventricle. The trachea was cannulated with a 
Vasofix
®
 Safety intravenous catheter and 2 ml of dispase followed by 0.5 ml of 1%  
low-melting point agarose was injected to the lungs. After 5 min, the lungs were 
removed, transferred into 2 ml of dispase and incubated for 45 min at RT. The lungs 
were dissected in 7 ml of DMEM medium without FCS (supplemented with 0.01% 
DNase I) and incubated for 10 min at RT. The resulting crude cell suspension was 
sequentially filtered through 100-μm and 40-μm cell strainers followed by final filtration 
through 20-μm nylon mesh. The filtrate was then centrifuged at 130 g for  
8 min at 4 °C and resuspended in 7 ml of erythrocyte lysis buffer and incubated for  
5 min at RT. Erythrocyte lysis was stopped with 7 ml of PBS, cells were centrifuged at 
130 g for 8 min at 4 °C and resuspended in 5 ml DMEM medium containing 10% FCS. 
The cells were then stained with trypan blue, counted using a Countess
®
 Cell Counter 
and incubated with 0.75 μl biotinylated anti-CD16/32, 0.9 μl biotinylated anti-CD45 and 
0.4 μl biotinylated anti-CD31 antibodies per 1 million cells, for 30 min at 37 °C. The 
cells were then washed with 5 ml of DMEM medium without FCS, and AETII cells 
were negatively selected using streptavidin-coupled Dynabeads
®
 for 30 min at RT with 
gentle mixing followed by final centrifugation at 130 g for 8 min at 4 °C and 
resuspension in DMEM medium with 10% FCS.  
 
DMEM medium without FCS Erythrocyte lysis buffer 
DMEM high glucose medium_ 0.1 mM Na2EDTA, pH 7.4_ 
10 mM HEPES, pH 7.2 _ 0.154 M NH4Cl_ 
1% penicillin/streptomycin solution_ 10 mM KHCO3_ 
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DMEM medium with 10% FCS _ 
DMEM high glucose medium_  
10 mM HEPES, pH 7.2_  
1% penicillin/streptomycin solution_  
10% FCS_  
 
3.2.4.2. Treatment of primary mouse alveolar epithelial type II cells 
The AETII cells were seeded on 12 mm diameter Snapwell™ inserts at  
a density of 5 × 10
5
 cells/well. After 24 h, the culture medium was removed from the 
apical compartment and the cells were grown under the air-liquid conditions. The cells 
were then treated with 10 ng/ml TGF-β1 for 48 h. For HDAC inhibition, 64 nM TSA,  
10 μM MGCD0103 or 10 μM MC1568 was added 24 h after TGF-β1 was introduced 
and incubated for another 24 h. 
 
3.2.5. Dual-luciferase reporter assay 
Firefly and Renilla luciferase activity in A549 cells transiently co-transfected 
with pGL3-Basic-ATP1B1-promoter firefly reporter and pRL-SV40 Renilla firefly  
co-reporter vectors was measured using the Dual-Luciferase
®
 reporter assay system. The 
co-transfected cells were lysed in 100 μl passive lysis buffer for 10 min in RT, with 
shaking at 100 rpm. Next, 5 μl of the cell lysate was transferred into 96-well plate, 
loaded into a Centro LB 960 microplate luminometer, and the activities of firefly and 
Renilla luciferases were measured sequentially in each well. The luminescence 
measurement protocol was as follows: dispersion of 50 μl of LAR II reagent (firefly 
luciferase substrate), quantification of luminescence for 7 s, dispersion of 50 μl  
Stop & Glo
®
 regent (containing inhibitor of firefly luciferase and substrate for Renilla 
luciferase) and quantification of luminescence for 7 s. The ATP1B1 promoter activity 
was expressed as ratio of firefly-to-Renilla luciferase luminescence signals. 
 
3.2.6. Gene expression analysis 
3.2.6.1. RNA isolation from lung tissue and from cell culture 
 Total lung RNA was isolated from 70-90 mg of tissue using 1 ml of TRIzol
®
 
reagent per 100 mg tissue. Lung tissue was homogenized in a Precellys
®
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24 homogenizer. Subsequently, 0.2 ml chloroform per 1 ml TRIzol
®
 reagent used for 
homogenization was added and samples were centrifuged at 12000 g for 15 min at 4 °C. 
After phase separation, the aqueous phase was transferred into a fresh 1.5 ml tube, and 
samples were combined with 0.5 ml 2-Propanol per 1 ml TRIzol
®
 reagent used for 
homogenization, and left for 10 min at RT. Next, samples were centrifuged at 12000 g 
for 10 min at 4 °C, the supernatant was removed and the RNA pellet was washed once 
with 1 ml of 75% ethanol. Quantification and purity of the isolated RNA was 
determined with a NanoDrop
®
 ND 1000. The cDNA was synthesized from RNA 
preparations with A260/280 absorbance ratio above 1.90.  
The total RNA from cells in culture was isolated using a NucleoSpin
®
 RNA II 
kit according to the manufacturer’s instructions. The quantification and purity of 
isolated RNA was determined with a NanoDrop
®
 ND 1000. The cDNA was synthesized 
from RNA preparations with A260/280 absorbance ratio above 1.90.  
 
3.2.6.2. cDNA synthesis 
Reverse transcription was performed on 500 ng of total RNA using MuLV 
reverse transcriptase and random hexamer oligodeoxyribonucleotides. To perform 
cDNA synthesis, 20 μl of RNA was denatured at 70 °C for 10 min, transferred onto ice, 
and supplemented with 20 μl of reverse transcription mixture. Afterwards, the mixture 
was incubated at 21 °C for 10 min, followed by an RNA synthesis step at 43 °C for  
1 h 15 min. The final incubation at 99 °C for 5 min was performed to inactivate MuLV 
reverse transcriptase.  
 
Reverse transcription mixture_ 
10× PCR buffer II_ 4 μl 
25 mM MgCl2_ 8 μl 
H2O_ 1 μl 
Random hexamers_ 2 μl 
RNase inhibitor_ 1 μl 
10 nM dNTP mix_ 2 μl 
MuLV reverse transcriptase_ 2 μl 
Total volume 20 μl 
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3.2.6.3. Real-time quantitative PCR 
Analysis of the gene expression at the mRNA level was performed by real-time 
quantitative polymerase chain reaction (qPCR) using a Platinum
®
 SYBR
®
 Green qPCR 
SuperMix UDG kit and a StepOnePlus™ Real-Time PCR System. Intron-spanning 
primer pairs specific to the target mRNA were designed using Primer-BLAST software 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Primers used in the gene expression 
analyses are listed in Table 3.  
 
Table 3. Primers used for gene expression analysis. 
Gene  Species Forward and reverse primers sequences 
ATP1A1 human 
5-AGCTACCTGGCTTGCTCTGTCC-3 
5-GCTGACTCAGAGGCATCTCCTGC-3 
ATP1B1 human 
5-AAAAGTACAAAGATTCAGCCCAGAGGG-3 
5-AGCTTGAATCTGCAGACCTTTCGC-3 
Atp1b1 mouse 
5-CCCAAGAGCTACGAGGCCTACG-3 
5-GTCGCCCCGTTCCTTGGGTTC-3 
FXYD1 human 
5-TCGCCGGGATCCTCTTCATCC-3 
5-CCCTCCTCTTCATCGGGTTCCCC-3 
FXYD2 human 
5-AATGGGGGCCTGATCTTC-3 
5-CTTCTTATTGCCCCCACAGC-3 
FXYD3 human 
5-AGCGCTCTGACATGCAGAAGGTG-3 
5-TCTTCTAGGTCATTGGCGTCCAGG-3 
FXYD4 human 
5-GCGGACTGATCTGCGGAGGG-3 
5-GCTGCTTCTGGCTGCTCTTGC-3 
FXYD5 human 
5-AGCAACTGGAAGGAACGGAT-3 
5-GGGTCTGTCTGGACGTCTGT-3 
FXYD6 human 
5-CCCCAGAAAGCAGAGAACTG-3 
5-GGCCGGTTTTCTTAAGCATC-3 
FXYD7 human 
5-TGTGGGCATGACTCTGGCAACC-3 
5-TGGAGTCCGCCTTCCTGCAC-3 
HPRT1 human 
5-AAGGACCCCACGAAGTGTTG-3 
5-GGCTTTGTATTTTGCTTTTCCA-3 
Hprt1 mouse 
5-GCTGACCTGCTGGATTAC-3 
5-TTGGGGCTGTACTGCTTA-3 
 
The thermal cycling conditions were as follows: 50 °C for 2 min, 95 °C for  
5 min, 40 cycles of 95 °C for 5 s, 59 °C for 5 s, 72 °C for 30 s. The samples were then 
subjected to melting curve analysis to ensure amplification of a single, specific product 
and to exclude the possibility of primer-dimer formation. A constitutively expressed 
human HPRT1 or mouse Hprt1 reference gene was used as a reference gene for  
qPCR reactions. Target gene expression was assessed with the comparative  
Ct method (ΔCt method) and calculated with the equation: ΔCt = CtHPRT1 − Cttarget.  
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3.2.7. Protein expression analysis 
3.2.7.1. Protein isolation 
The entire protein isolation procedure was carried out on ice to prevent protein 
degradation. Protein lysis buffer was supplemented with 1 mM sodium orthovanadate 
and Complete™ protease inhibitor cocktail (1 tablet per 25 ml of protein lysis buffer) 
immediately before use. Next, 100 μl or 200 μl of protein lysis buffer was added to the 
A549 cells seeded on 6-well or 12-well plates, respectively, and cells were collected 
with a cell scraper into a 1.5 ml tube and incubated for 30 min with occasional vortexing. 
Tubes were then centrifuged at 13000 rpm for 15 min at 4 °C and the supernatant was 
then transferred into fresh 0.5 ml tubes. To measure protein concentration, samples as 
well as protein lysis buffer were diluted 1:10 with water and 10 μl was transferred into a 
96-well plate. In parallel, a series of 10 μl of bovine serum albumin protein standards 
were included on the same plate. Subsequently, 100 μl of Quick Start™ Bradford dye 
regent was added to each well, plate was left for 5 min and the absorbance was 
measured at a 570 nm wavelength using a VersaMax micro-plate reader. Protein 
concentrations were calculated for each sample using a standard curve. 
 
Protein lysis buffer_ 
150 mM NaCl_ 
1 mM EDTA_ 
1 mM EGTA_ 
0.5% Igepal
®
 CA-630_ 
20 mM Tris-Cl, pH 7.5_ 
 
3.2.7.2. Protein electrophoresis and western blot 
Protein samples were mixed with 10× sample buffer and resolved by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis at 110 mV in running buffer. After 
the bromophenol blue tracking dye had left the resolving gel, proteins were blotted onto 
a nitrocellulose membrane at 110 mV for 1 h in blotting buffer. Next, the membrane was 
washed once with washing buffer and incubated for 1 h in blocking buffer at RT. 
Membranes were then incubated with primary antibody diluted in blocking buffer at  
4 °C overnight. Primary antibodies used in the western blot analysis are listed in  
Table 4. After the membrane was rinsed in washing buffer four times for 3 min each, the 
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horseradish peroxidase-conjugated secondary antibody diluted in blocking buffer was 
then added, and the membrane was incubated for 1 h at RT. Thereafter, the membrane 
was rinsed four times for 3 min each in washing buffer, and was incubated in 
SuperSignal
®
 West Femto chemiluminescent substrate for 3 min at RT. The protein 
bands were visualized and archived with a LAS-4000 luminescent image analyzer. 
 
Table 4. Primary antibodies used in western blot analysis. 
Antibody Dilution Company Catalog number 
Anti-β-ACTIN 1:1000 Cell Signaling Technology, USA 4967L 
Anti-E2F4 1:100 Santa Cruz Biotechnology, USA sc-1082 
Anti-E2F5 1:100 Santa Cruz Biotechnology, USA sc-999 
Anti-HDAC1 1:500 Cell Signaling Technology, USA 2062 
Anti-HDAC2 1:500 Santa Cruz Biotechnology, USA sc-6296 
Anti-HDAC2  
(phospho S394) 
1:500 Abcam, UK ab75602 
Anti-HDAC3 1:500 Santa Cruz Biotechnology, USA sc-8138 
Anti-LAMIN A/C 1:5000 Santa Cruz Biotechnology, USA sc-20681 
Anti-RUNX2 1:500 Invitrogen, USA 41-1400 
Anti-SMAD2 1:1000 Cell Signaling Technology, USA 3103 
Anti-SMAD2 
(phospho S465/467) 
1:1000 Cell Signaling Technology, USA 3101S 
Anti-SMAD3 1:1000 Cell Signaling Technology, USA 3102 
Anti-SMAD3 
(phospho S423/425) 
1:1000 Cell Signaling Technology, USA 9520S 
Anti-SMAD4 1:500 Cell Signaling Technology, USA 9515 
Anti-SNAI1 1:500 R&D Systems, USA AF3639 
Anti-SNON 1:500 Cell Signaling Technology, USA 4973 
Anti-YY1 1:500 Santa Cruz Biotechnology, USA sc-7341 
 
 
 
10× Sample buffer 10% Resolving gel 
650 mM Tris-Cl, pH 6.8_ 10% acrylamide/bisacrylamide mixture_ 
1 mM EDTA_ 375 mM Tris-Cl, pH 8.8_ 
50% glycerol_ 0.05% SDS_ 
0.3% bromophenol blue_ 0.05% APS_ 
9% β-mercaptoethanol_ 0.065% TEMED_ 
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Stacking gel Running buffer 
5% acrylamide/bisacrylamide mixture _ 250 mM Tris-Cl, pH 8.3_ 
125 mM Tris-Cl, pH 6.8_ 2.5 M glycine_ 
0.05% SDS_ 1% SDS_ 
0.05% APS_  
0.065% TEMED_ Washing buffer 
 1× PBS, pH 7.2_ 
Blotting buffer 0.1% Tween
® 
20_ 
25 mM Tris-Cl, pH 8.3_  
192 mM glycine_ Blocking buffer 
20% methanol_ 1× PBS, pH 7.2_ 
 0.1% Tween
® 
20_ 
 5% non-fat dry milk_ 
 
 
3.2.8. Chromatin immunoprecipitation 
Chromatin immunoprecipitation (ChIP) assay was performed on A549 cells 
plated on 60 mm dishes. Cells were cultured until 90% confluence was reached and 
stimulated with 10 ng/ml TGF-β1 for 3 h. Cells were then washed with PBS twice,  
and subjected to dual cross-linking with 1 mM 3,3′-Dithiodipropionic acid  
di(N-hydroxysuccinimide ester) (DSP) in PBS for 30 min followed by incubation with 
1% formaldehyde for 10 min at RT, with shaking at 100 rpm. Cross-linking was 
quenched with 125 mM glycine for 5 min at RT. After a single washing step with PBS, 
the procedure was carried out on ice to prevent the degradation of protein and DNA. 
Cells were lysed for 10 min in 1 ml of RIPA buffer supplemented with 1 mM sodium 
orthovanadate and Complete™ protease inhibitor cocktail (1 tablet per 25 ml of RIPA 
buffer). The lysate was collected with a cell scraper into a 1.5 ml tube and chromatin 
was sheared into 200-300 bp-long fragments using a Sonopuls HD 2070 ultrasonic 
homogenizer using the following settings: 7 rounds of 10 pulses with 40% duty cycle 
and 40% power output settings. The lysate was then centrifuged at 14000 rpm for  
15 min, and the supernatant was collected. The 163 μl of supernatant was diluted 1:6 in 
RIPA buffer and pre-cleared with 50 μl protein A/G agarose beads saturated with 10 μg 
of sonicated salmon sperm DNA for 1 h with gentle orbital rotation. After the 
centrifugation at 3000 rpm for 4 min, protein A/G agarose beads were discarded, and the 
immunoprecipitation was carried out with 20 μg of anti-HDAC2 or normal rabbit IgG 
Materials and methods 
 44 
antibodies added to the pre-cleared chromatin lysate. Two hours later, 50 μl protein A/G 
agarose beads saturated with 10 μg of sonicated salmon sperm DNA was added and left 
overnight with gentle orbital rotation. Antibody-chromatin complexes conjugated to 
protein A/G agarose beads were then sequentially washed with 1 ml of low salt buffer,  
1 ml high salt buffer, 1 ml LiCl buffer and twice with 1 ml TE buffer. Each washing step 
was conducted for 5 min followed by centrifugation at 3000 rpm for 3 min at RT and 
removal of the supernatant. To elute antibody-chromatin complexes, 150 μl elution 
buffer was added and samples were incubated for 30 min at 65 °C with shaking at  
500 rpm. Samples were centrifuged at 3000 rpm for 3 min at RT and the supernatant 
was saved in a fresh 1.5 ml tube. To test the efficiency of the antibody to 
immunoprecipitate HDAC2, 36 μl of eluate or input samples was subjected to protein 
electrophoresis and western blot as described above. To purify DNA from protein, 
immunoprecipitated chromatin was reverse cross-linked at 65 °C followed by addition 
of 50 mM DTT and incubation for 30 min at 37 °C and 0.5 μg/ml proteinase K treatment 
for 30 min at 55 °C. The DNA was further purified using QIAquick PCR purification kit 
according to the manufacturer instructions. Semi-quantitative PCR and qPCR were then 
performed using Platinum
®
 SYBR
®
 Green qPCR SuperMix UDG kit on 4 ng of DNA. 
Primers used in the ChIP experiments are listed in Table 5. The product of the  
semi-quantitative PCR were resolved on 3% agarose gel containing 0.5 μg ethidium 
bromide and archived using X Omat 2000 developer.  
  
Low salt buffer_ LiCl buffer 
0.1% SDS_ 0.25 M LiCl_ 
1% Triton X-100_ 1% Igepal
®
 CA-630_ 
2 mM EDTA_ 1% deoxycholate_ 
20 mM Tris-Cl, pH 8.0_ 1 mM EDTA_ 
150 mM NaCl_ 10 mM Tris-Cl, pH 8.0_ 
  
High salt buffer TE buffer 
0.1% SDS_ 1 mM EDTA_ 
1% Triton X-100_ 10 mM Tris-Cl, pH 8.0_ 
2 mM EDTA_  
20 mM Tris-Cl, pH 8.0_ Elution buffer_ 
500 mM NaCl_ 1% SDS, pH 8.0_ 
 0.1 M NaHCO3, pH 8.0_ 
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Table 5. Primers used in chromatin immunoprecipitation experiments. 
Locus Forward and reverse primers sequences 
ATP1B1 promoter 
5-CCCCCAAGGGGGCATAAAAGCA-3 
5-AGGCACAATATCTGCACGTGACC-3 
HPRT1 exon three 
5-ACGTCTTGCTCGAGATGTGAT-3 
5-GATGTAATCCAGCAGGTCAGC-3 
 
3.2.9. Animal experiments 
3.2.9.1. The bleomycin model of acute respiratory distress syndrome 
and trichostatin A treatment 
Animal experiments were approved by local authorities (Regierungspräsidium 
Darmstadt, approval number B 2/281). Male mice (C57BL/6J) were obtained from 
Charles River Laboratories, Sulzfeld, Germany. Only animals weighing 20-25 g were 
used in the study. Mice were anesthetized with mixture of 100 mg ketamine per kg body 
weight and 8 mg xylazine per kg body weight. Thereafter, mice were orotracheally 
intubated and mechanically ventilated. Bleomycin (5 U per kg body weight) or 0.9% 
saline was then intratracheally instilled using a microsprayer. After 24 h, mice received 
an intraperitoneal injection of 0.5 mg TSA per kg body weight or 0.9% saline which was 
repeated daily for 3 subsequent days. At the conclusion of the experiment, mice were 
sacrificed with 500 mg pentobarbital per kg body weight. 
 
3.2.9.2. Lung tissue collection and weight measurements 
After the thoracic cavity was exposed, lungs were perfused with 1× PBS injected 
via the right ventricle. The trachea was then dissected and lung was removed. The right 
lung was snap-frozen in liquid nitrogen and subjected to RNA isolation and gene 
expression analysis as described above. The left lobe was used to assess the lung  
wet-to-dry weight ratio by the gravimetric method. After the wet lung weight was 
measured, the lung was incubated at 60 °C for 72 h in an oven. Then, the dry lung 
weight was measured and ratio between wet and dry left lung weights was calculated.  
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3.2.9.3. Broncho-alveolar lavage 
The lung and trachea were exposed as described above. After the lung was 
cannulated via the trachea, the left main bronchus was clamped and the right lung was 
lavaged three times with 300 μl 0.9% NaCl. The clamp was then removed, attached to 
the right main bronchus, and the lavage was collected from the left lung. The BAL fluid 
was collected after each wash and pooled. Subsequently, BAL fluid was centrifuged at 
1780 rpm for 10 min at 4 °C. The supernatant and cell pellet were collected separately 
and used for protein concentration measurements and analyses of inflammatory cell 
populations, respectively.  
 
3.2.9.4. Measurement of protein concentration in broncho-alveolar 
lavage fluid 
To measure protein concentration, 10 μl BAL fluid supernatant, 0.9% NaCl and 
bovine serum albumin protein standard were transferred into a 96-well plate. Next,  
200 μl of Pierce® BCA protein assay reagent was added to each well, plate was 
incubated at 37 °C for 30 min and absorbance was measured at 562 nm wavelength 
using a VersaMax micro-plate reader. Protein concentrations in BAL fluid were 
calculated for each sample using a standard curve. 
 
3.2.9.5. Analysis of inflammatory cell populations 
The cell pellet formed after BAL fluid centrifugation was resuspended in 1 ml of 
0.9% NaCl. Subsequently, 100 μl of cell suspension was loaded onto assembled 
CellSpin preparation system and centrifuged at 500 rpm for 5 min. Slides were then 
dried and cells were stained with May-Grünwald solution for 5 min followed by 
incubation in Giemsa solution diluted 1:10 in water for 10 min. The differential cell 
count of alveolar macrophages, neutrophils and lymphocytes was then made under a 
light microscope and expressed as a percentage of the total cell population in the BAL 
fluid.  
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3.2.9.6. Evans blue extravasation assay 
Evans blue dye (20 mg per kg body of weight) was injected into the tail vein 3 h 
before mice were sacrificed. At the time of killing, 1 ml of blood was collected by 
cardiac puncture, centrifuged at 1300 rpm for 10 min at RT and the blood plasma was 
diluted in formamide 1:100. The lung was perfused with PBS via the right ventricle, 
homogenized in a Precellys
®
 24 homogenizer and diluted in two volumes of formamide. 
Blood plasma and lung homogenate samples diluted in formamide were then incubated 
at 60 °C for 16 h to extract the Evans blue dye. Subsequently, the lung homogenate was 
centrifuged at 5000 g for 30 min at RT and the pellet was discarded. The absorbance  
of Evans blue in blood plasma and lung homogenate was then measured at  
620 nm and corrected for the presence of heme by absorbance measurements at  
740 nm. The corrected Evans blue absorption was then calculated as follows  
A620 (corrected) = A620 − (1.426 × A740 + 0.03) for lung homogenates and blood plasma. The 
Evans blue index reflecting the microvascular permeability of the dye was expressed as 
ratio of A620 (corrected) in the lung homogenate to the A620 (corrected) in the blood plasma.  
 
 
3.3. Statistical analyses 
Values are presented as mean ± SEM. Statistical comparisons between means of 
two groups were performed using unpaired Student’s t-tests. For multiple comparisons, 
statistical analysis was performed using one-way ANOVA followed by a Tukey’s  
post-hoc test. P-values less than 0.05 were considered significant. 
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4. Results 
4.1. Pulmonary expression of genes encoding Na,K-ATPase 
subunits in lungs from acute respiratory distress 
syndrome patients and in healthy lung tissue  
The expression of the ATP1A1, ATP1B1 and FXYD1-FXYD7 genes encoding  
Na,K-ATPase subunits in lung tissue from patients with ARDS was analyzed by qPCR. 
The expression of genes in lung homogenates was compared between four donors and 
five ARDS patients. The downregulation of ATP1B1 gene expression was noted in 
samples from ARDS patients when compared to apparently healthy lung donors as 
depicted in Figure 6. Moreover, the expression of the FXYD1 and FXYD3 genes was 
significantly upregulated in ARDS patients, while ATP1A1, FXYD2 and FXYD4-FXYD7 
gene expression remained unchanged comparing the two sample groups. 
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Figure 6. Pulmonary expression of genes encoding Na,K-ATPase subunits in donor versus ARDS 
patients. The expression of the ATP1A1, ATP1B1 and FXYD1-FXYD7 genes was assessed in lung tissue 
from five patients with ARDS or four healthy lung donors by qPCR. Data are expressed as mean ± SEM. 
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4.2. TGF-β alters the expression of genes encoding  
Na,K-ATPase subunits in A549 cells 
The A549 cell-line is frequently used as a model for the human alveolar 
epithelium. In order to verify whether TGF-β has a regulatory role governing the 
expression of genes encoding Na,K-ATPase subunits in an epithelial-like cell-line, 
qPCR analysis was performed. Figure 7 depicts the diverse effect of TGF-β on the 
expression of Na,K-ATPase subunits encoding genes.  
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Figure 7. Expression of genes encoding Na,K-ATPase subunits in TGF-β-treated A549 cells. The 
expression of the ATP1A1, ATP1B1 and FXYD1-FXYD7 genes was assessed in the A549 cells stimulated 
with 0-10 ng/ml of TGF-β1 for 24 h or 48 h by qPCR (n=3, per group). Data are expressed as  
mean ± SEM.  
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The TGF-β treatment induced expression of ATP1A1, FXYD1, FXYD5 and 
FXYD6 genes and decreased the expression of ATP1B1, FXYD2, FXYD3 and FXYD4 
genes. The expression of FXYD7 remained unaffected. Furthermore, the effect of  
TGF-β on FXYD3 mRNA abundance was time-dependent as only TGF-β treatment for 
48 h but not 24 h caused repression of this gene. Additionally, genes ATP1A1, FXYD1, 
FXYD2, FXYD5 and FXYD6 were dose-dependently regulated by TGF-β. 
 
4.3. Inhibition of TGF-β signaling restores ATP1B1 gene 
expression  
TGF-β utilizes SMAD2 and SMAD3 transcription factors as primary mediators 
of the TGF-β-regulated gene expression program. To test whether SMAD2 and SMAD3 
were implicated in regulation of the ATP1B1 gene, A549 cells were pre-treated with 
SB431542, a selective inhibitor of the TBRI receptors, ALK4, ALK5 and ALK7, and 
then stimulated with TGF-β. As demonstrated in Figure 8A and 8B, treatment with 
SB431542 drastically reduced phosphorylation of the SMAD2 and SMAD3 in the  
TGF-β-treated cells. Furthermore, SB431542 prevented repression of the ATP1B1 gene 
indicating that TGF-β signaling employs R-SMADs to regulate expression of the 
ATP1B1 gene (Figure 8C). 
 
   
p=0.0449
- + - +
0.0
0.5
1.0
1.5
2.0
TGF-
SB431542 - - + +
p=0.3511

C
t
   
 
Figure 8. Inhibition of the TGF-β type I receptor alleviates ATP1B1 gene repression by TGF-β. The 
impact of SB431542 on the phosphorylation of SMAD2 (A) and SMAD3 (B). The A549 cells were first 
treated with 20 μM SB431542 for 1 h followed by stimulation with 10 ng/ml TGF-β1 for 1 h. Total 
cellular proteins were isolated, subjected to western blot and immunohistochemically stained with 
antibodies against phosphorylated SMAD2, phosphorylated SMAD3, total SMAD2, total 
SMAD2/SMAD3 and β-ACTIN. (C) Expression analysis of the ATP1B1 gene was assessed in A549 cells 
stimulated with 0 ng/ml or 10 ng/ml of TGF-β1 for 48 h, by qPCR. The 20 μM SB431542 was added 1 h 
before the TGF-β1 stimulation for 49 h (n=3, per group). Data are expressed as mean ± SEM. 
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4.4. TGF-β downregulates ATP1B1 gene expression via 
SMAD2, SMAD4, SNAI1 and E2F5 transcription factors 
TGF-β signaling is a complex process involving the activity of many different 
transcription factors in order to achieve precise regulation of target gene expression. In 
order to characterize the transcription factors involved in the TGF-β-dependent  
down-regulation of the ATP1B1 gene, a series of knock-down experiments was 
performed. Lipofectamine™ 2000-mediated delivery of siRNA molecules designed 
against TGF-β signaling-associated transcription factors was selected to take advantage 
of the relatively efficient transfection rates of A549 cells using cationic lipid 
formulations. At the 24 h or 48 h time-point before TGF-β stimulation, A549 cells were 
transfected with 100 nM or 200 nM siRNA targeting the SMAD2, SMAD3, SMAD4, 
YY1, RUNX2, TGIF, SNON, SNAI1, E2F4 and E2F5 transcription factors, which led to 
a marked decrease in protein abundance as demonstrated by western blot (Figure 9).  
 
    
 
 
     
 
 
      
 
Figure 9. Optimization of siRNA knock-down of transcription factors involved in TGF-β signaling. 
The A549 cells were transfected with 100 nM or 200 nM of scrambled (scr) siRNA or siRNA designed 
against SMAD2 (A), SMAD3 (B), SMAD4 (C), YY1 (D), RUNX2 (E), SNON (F), SNAI1 (G), E2F4 (H) 
or E2F5 (I) for 24 h and 72 h or 48 h and 96 h. A western blot was used to confirm the knock-down of 
transcription factor proteins. 
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An analysis of ATP1B1 gene expression by qPCR revealed that the depletion of 
SMAD3, YY1, RUNX2, TGIF, SNON and E2F4 transcription factors did not impact the 
ability of TGF-β to down-regulate the ATP1B1 gene expression (Figure 10B,  
10D-F and 10H). However, the ATP1B1 gene was relieved from repression by TGF-β in 
cells where SMAD2, SMAD4, SNAI1 or E2F5 were depleted by knock-down (Figure 
10A, 10C, 10G and 10I). These data indicate that SMAD2, SMAD4, SNAI1 and E2F4 
mediate the downregulation of ATP1B1 gene expression by TGF-β.  
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Figure 10. Regulation of the ATP1B1 gene by TGF-β signaling-associated transcription factors. 
Expression of the ATP1B1 gene in A549 cells with knock-down of SMAD2 (A), SMAD3 (B), SMAD4 
(C), YY1 (D), RUNX2 (E), SNON (F), SNAI1 (G), E2F4 (H) or E2F5 (I) transcription factors. The A549 
cells were transfected with 100 nM or 200 nM of siRNA. At 24 h or 48 h later, 10 ng/ml of  
TGF-β1 was added to transfection medium for additional 48 h. The expression of ATP1B1 gene was then 
analyzed by qPCR (n=3, per group). Data are expressed as mean ± SEM.  
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4.5. TGF-β downregulates ATP1B1 promoter activity 
To confirm that TGF-β signaling controls the expression of the ATP1B1 gene at 
the level of gene transcription, the 1837-bp DNA fragment spanning the upstream region 
the ATP1B1 gene (-3075 to -1238 bp upstream from transcription start site) was cloned 
into pGL3-Basic vector. The activity of the ATP1B1 promoter was measured by a  
dual-luciferase
 
reporter assay. TGF-β significantly decreased the activity of ATP1B1 
promoter (Figure 11A) revealing that TGF-β inhibits the expression of the ATP1B1 gene 
on the transcription level.  
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Figure 11. The ATP1B1 promoter analysis in A549 cells treated with TGF-β. (A) A dual-luciferase 
reporter assay of ATP1B1 gene promoter activity. Cells were transiently co-transfected with a  
pGL3-Basic-ATP1B1-promoter firefly luciferase reporter plasmid and pRL-SV40 Renilla luciferase  
co-reporter vector and were then stimulated with 0-10 ng/ml TGF-β1 for 48 h (n=4, per group). Data are 
expressed as mean ± SEM. (B) Schematic representation of 3 kbp region of the ATP1B1 promoter. Novel 
putative bindings sites for E2F5 (-2118 bp) and SNAI1 (-1562 bp) along previously characterized SNAI1 
binding site (-71 bp) are shown. (C) Sequence comparison of the E2F5 binding element from c-myc 
promoter to putative E2F5 binding site in the ATP1B1 promoter. Differing nucleotides are underlined. 
 
 
Sequence analysis of the promoter region spanning 3000 bp upstream from the 
transcriptional start site revealed the presence of putative binding sites for SNAI1 and 
E2F5 transcription factors. The noncanonical E-box element, a SNAI1-binding 
sequence, located within -71 to -66 bp upstream from transcription start site was 
previously characterized (Espineda et al., 2004). Analysis of the further upstream 
regions of the promoter uncovered a site identical in sequence to the E-box element  
(5-CCGGTG-3) characterized by Espineda et al. albeit -1562 to -1557 bp upstream 
from the transcriptional start site (Figure 11B). Additionally, a site highly similar  
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to the E2F5-binding element reported by Chen and coworkers was located at -2118 to  
-2110 bp (Figure 11C). The putative E2F5 binding site localized in the ATP1B1 gene 
promoter varied from the TGF-β responsive element described in the c-myc promoter by 
the presence of the single thymine base instead of the guanine at position seven of the 
sequence (Chen et al., 2002). 
 
4.6. The TGF-β-dependent down-regulation of ATP1B1 gene 
expression is mediated by DNA methylation and class I 
histone deacetylases  
To test whether inhibition of ATP1B1 expression by TGF-β involves the action 
of the epigenetic machinery, 5-Aza-2′-dC and TSA were employed to inhibit DNA 
methylation and histone deacetylation, respectively. Prevention of DNA methylation by 
5-Aza-2′-dC abolished TGF-β-triggered downregulation of the ATP1B1 gene expression 
as assessed by qPCR (Figure 12A). Additionally, the influence of DNA methylation on 
the ATP1B1 promoter was tested. The treatment with 5-Aza-2′-dC alone reduced the 
activity of the ATP1B1 promoter to the level observed under the TGF-β conditions. 
Moreover, TGF-β did not further reduce the activity of the ATP1B1 promoter in A549 
cells co-treated with 5-Aza-2′-dC (Figure 12B).  
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Figure 12. Activity of the ATP1B1 gene and promoter is regulated by DNA methylation. 
(A) Analysis of ATP1B1 gene expression in A549 cells stimulated with 0 ng/ml or 10 ng/ml of  
TGF-β1 for 48 h by qPCR (n=3, per group). 24 h before TGF-β1 treatment and at the 0 h and 24 h  
time-points after TGF-β1 stimulation, 0, 0.1 or 10 μM 5-Aza-2′deoxycytidine (5-Aza-2′-dC) was added. 
(B) A dual-luciferase reporter assay of the ATP1B1 promoter activity (n=9, per group). Cells were 
stimulated with TGF-β1 or 5-Aza-2′-dC as in (A). Data are expressed as mean ± SEM.  
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To test whether TGF-β signaling recruits HDACs to repress the ATP1B1 gene, 
the pan-HDAC inhibitor, TSA, was used. Histone deacetylase inhibition abrogated the 
repression of the ATP1B1 gene by TGF-β (Figure 13A). Moreover, the involvement of 
HDACs in the repression was further confirmed by evidence of decreased ATP1B1 
promoter activity in the TGF-β stimulated cells co-treated with TSA (Figure 13C). To 
characterize the nature of the complexes repressing the ATP1B1 gene, class-specific 
inhibitors of HDAC enzymes were employed. The TGF-β-induced repression of the 
ATP1B1 gene was specifically facilitated by class I HDAC enzymes, since use of the 
class I HDAC inhibitor MGCD0103 but not MC1568 (a class II HDAC inhibitor) 
removed the TGF-β effect (Figure 13B). Moreover, the involvement of class I HDAC 
has been verified by promoter activity assay, where MGCD0103 alleviated the  
response to TGF-β, while use of the class II HDAC inhibitor did not repeat this result  
(Figure 13C).  
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Figure 13. Class I histone deacetylases regulate ATP1B1 gene expression and promoter activity.  
(A), (B) and (C) The A549 cells were stimulated with 0 ng/ml or 10 ng/ml of TGF-β1 for 48 h. At 24 h 
after TGF-β1 was added, 64 nM pan-HDAC inhibitor trichostatin A (TSA), 10 μM (C) class I or class II 
HDAC inhibitors (MGCD0103 or MC1568, respectively) were added for 24 h (n=3-4, per group). (A) and 
(B) Expression of the ATP1B1 was assessed by qPCR. (C) A dual-luciferase
 
reporter assay of the ATP1B1 
promoter activity (n=3, per group). Data are expressed as mean ± SEM.  
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4.7. Histone deacetylase 2 mediates repression of the ATP1B1 
gene by TGF-β  
To characterize which member of the class I HDACs repress ATP1B1 gene 
expression after TGF-β stimulation, the siRNA approach was employed to knock-down 
HDAC1, HDAC2 and HDAC3 proteins. As demonstrated in Figure 14A-C, the control 
western blot confirmed that siRNA transfections decreased the abundance of HDAC1, 
HDAC2 and HDAC3 proteins. The knock-down of the HDAC2 expression by siRNA 
resulted in a diminished effect of TGF-β on ATP1B1 gene expression (Figure 14E). This 
effect was specific only to cells displaying HDAC2 knock-down, since depletion of 
HDAC1 or HDAC3 did not impact ATP1B1 gene repression (Figure 14D and 14F).  
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Figure 14. A particular role for histone deacetylase 2 in the regulation of ATP1B1 gene repression. 
Optimization of siRNA knock-down of HDAC1 (A), HDAC2 (B) or HDAC3 (C) transcription co-factors. 
The A549 cells were transfected with 200 nM of scrambled (scr) siRNA or siRNA designed against one of 
the HDAC-encoding mRNA for 24 and 72 or 48 and 96 h. A western blot was used to confirm  
knock-down of HDAC protein. Expression of the ATP1B1 gene in A549 cells with knock-down of 
HDAC1 (D), HDAC2 (E) or HDAC3 (F) proteins. The A549 cells were transfected with 200 nM of 
siRNA. At 24 or 48 h later, 10 ng/ml of TGF-β1 was added to transfection medium for additional 48 h. 
The expression of the ATP1B1 gene was then analyzed by qPCR (n=3, per group). Data are xpressed as 
mean ± SEM.  
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4.8. Histone deacetylase 2 occupies the ATP1B1 promoter 
and is activated by TGF-β  
To investigate whether HDAC2 can be located in the ATP1B1 gene promoter a 
ChIP technique was employed. In principle, the ChIP assay allows for the detection of a 
specific DNA sequence which interacts with immunoprecipitated proteins of interest. As 
a transcriptional co-repressor, HDAC2 does not bind DNA directly, and is not located in 
close proximity to DNA, which limits the effectiveness of the short-arm cross-linker 
formaldehyde that is commonly used in the ChIP assay. In the present study, the  
DNA-protein cross-linking procedure was modified by the introduction of the long-arm 
cross-linker DSP to capture the weak association between HDAC2 and DNA. 
Immunoprecipitation of the HDAC2 was confirmed by western blot by identification of 
a band migrating with a molecular mass of 55 kDa (Figure 15A). As a 55 kDa band was 
not detected when an isotype control antibody was used instead of an anti-HDAC2 
antibody, the specificity of the HDAC2 immunoprecipitation was confirmed. Analysis 
of DNA cross-linked to HDAC2 by PCR resulted in amplification of ATP1B1 promoter 
region located -1339 to -1241 bp upstream from the transcriptional start site  
(Figure 15B). The TGF-β treatment for 3 h did not impact the intensity of the -1339 to  
-1241 bp amplicon, suggesting that TGF-β does not increase ATP1B1 promoter 
occupancy by HDAC2. The absence of DNA amplification when an isotype control 
antibody was used confirmed the specificity of the ChIP. To further test the specificity 
of the ChIP assay, exon three of the reference gene HPRT1 was chosen to represent a 
region potentially uninvolved in transcriptional regulation and HDAC2 binding. No 
DNA amplification was observed when semiquantitative PCR with primers recognizing 
exon three in HPRT1 gene was performed on chromatin immunoprecipitated with an 
anti-HDAC2 or isotype control antibody (Figure 15C). These data suggest that 
immunoprecipitates were not contaminated with DNA fragments which were not bound 
to HDAC2. To obtain quantitative data for TGF-β impact on the sequestration of the 
HDAC2 to the ATP1B1 promoter, a qPCR technique was employed. As illustrated in 
Figure 15D, TGF-β treatment did not significantly induce the accumulation of HDAC2 
in region -1339 to -1241 bp of the ATP1B1 promoter, thereby confirming that TGF-β 
does not increase the occupancy of HDAC2 on the ATP1B1 promoter.  
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Figure 15. Histone deacetylase 2 occupancy of the ATP1B1 promoter. (A) Control western blot 
confirming specific immunopreciopitation of HDAC2. (B), (C) and (D) ChIP assay of the HDAC2 
enrichment in the ATP1B1 promoter region located -1339 to -1241 bp upstream from transcriptional start 
site in A549 cells stimulated with 0 or 10 ng/ml TGF-β1 for 3 h. (B) PCR amplification of the ATP1B1 
promoter. (C) PCR amplification of exon three of the HPRT1 gene. (D) Fold-change of the relative 
ATP1B1 promoter DNA abundance assessed by qPCR. IgG, Immunglobulin G; In, Input; IP:HDAC2, 
immunoprecipitation with anti-HDAC2 antibody; IP:CTRL, immunoprecipitation with isotype-matched 
nonspecific antibody (n=3, per group).  
 
 
Since TGF-β treatment did not increase enrichment of HDAC2 at the ATP1B1 
promoter site, the possibility that TGF-β signaling can regulate HDAC2 activity was 
investigated. The phosphorylation of HDAC2 at serine 394 has been linked to  
increased enzymatic activity and speculated to be an important step allowing the  
formation of repressor complexes (Tsai and Seto, 2002). Therefore, the impact of  
TGF-β on the phosphorylation at serine 394 of HDAC2 was evaluated by western blot. 
As depicted in Figure 16, treatment with TGF-β increased phosphorylation of serine 394 
which was observed over 3 h time course after stimulation indicating that TGF-β 
signaling can activate HDAC2.  
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Figure 16. Impact of TGF-β on the phosphorylation status of HDAC2. The A549 cells were 
stimulated with 0 ng/ml or 10 ng/ml of TGF-β1 for 1, 2 or 3 h. Total cellular proteins were isolated, 
subjected to western blot and immunochemically stained with antibodies against HDAC2 phosphorylated 
at serine 394, total HDAC2 and LAMIN A/C (n=4, per group). 
 
 
4.9. Downregulation of the Atp1b1 gene in TGF-β-stimulated 
alveolar epithelial type II cells can be reversed by 
inhibition of class I histone deacetylases 
Isolated primary mouse AETII cells were used to verify whether TGF-β 
regulates Atp1b1 gene expression in epithelial cells in primary culture. As demonstrated 
in Figure 17, treatment with TGF-β for 48 h resulted in repression of the Atp1b1 gene in 
primary AETII cells cultured under air-liquid conditions.  
To test whether HDAC proteins mediate regulation of the Atp1b1 gene by  
TGF-β, the pan-HDAC inhibitor TSA was employed. The TGF-β stimulation increased 
the expression of the Atp1b1 gene in TSA-treated AETII cells (Figure 17). The 
MGCD0103 and MC1568 inhibitors were used to discriminate which class of HDAC 
enzymes was involved in the regulation of the Atp1b1 gene by TGF-β in mouse AETII 
cells. The Atp1b1 gene was released from the TGF-β-controlled repression exclusively 
in AETII cells co-treated with MGCD0103 (class I HDAC inhibitor). Conversely, use of 
the class II HDAC inhibitor, MC1568, did not influence the TGF-β-induced repression 
of the Atp1b1 gene (Figure 17). These data confirm a key role for class I HDACs in the 
repression of the ATP1B1 gene by TGF-β in alveolar epithelial cells.  
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Figure 17. Regulation of Atp1b1 gene expression in alveolar epithelial type II cells by TGF-β and 
class I histone deacetylases. Analysis of Atp1b1 gene expression in primary mouse alveolar epithelial 
type II cells stimulated with 0 ng/ml or 10 ng/ml of TGF-β1 for 48 h by quantitative PCR. At  
24 h after TGF-β1 stimulation, 64 nM pan-HDAC inhibitor trichostatin A (TSA), 10 μM class I or  
class II HDAC inhibitors (MGCD0103 or MC1568, respectively) were added for 24 h (n=3, per group). 
Data are expressed as mean ± SEM.  
 
 
4.10. Histone deacetylase inhibition rescues Atp1b1 gene 
expression and decreases lung water content in the 
bleomycin model of acute respiratory distress syndrome  
Several groups have reported TGF-β signaling to be deregulated and to mediate 
ARDS in human patients and lung injury in various animal models of ARDS (Budinger 
et al., 2005, Wesselkamper et al., 2005, Dhainaut et al., 2003, Fahy et al., 2003, Pittet et 
al., 2001). Here, TGF-β signaling has been reported to employ HDAC2 to downregulate 
ATP1B1 gene expression in A549 cells which could be alleviated by HDAC2 inhibition. 
Moreover, Atp1b1 gene expression was downregulated in primary mouse AETII cells 
treated with TGF-β, and this effect was alleviated by HDAC inhibition. Therefore, the 
impact of the pan-HDAC inhibitor TSA on the expression of the Atp1b1 gene in  
bleomycin model of ARDS has been investigated. Expression of the Atp1b1 gene in 
murine lungs five days post-bleomycin instillation was reduced (Figure 18A) while lung 
water content was increased (Figure 18B). Remarkably, administration of the TSA to 
bleomycin-instilled mice restored the expression of the Atp1b1 gene (Figure 18A). 
Moreover, increased Atp1b1 gene expression by TSA was accompanied by decreased 
lung water (Figure 18B) when compared to bleomycin-only treated mice. Based on these 
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data, it can be concluded that histone deacetylases mediate the repression of the Atp1b1 
gene in vivo and are involved in modulation of pulmonary edema. 
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Figure 18. Effect of trichostatin A on Atp1b1 gene expression and pulmonary edema in the 
bleomycin model of acute respiratory distress syndrome. C57BL/6J mice were instilled with 
bleomycin to initiate lung injury. At 24 h later, mice received intraperitoneal injection of trichostatin A 
(TSA) or vehicle for four subsequent days. After animals were sacrificed, RNA was isolated and Atp1b1 
gene expression was analyzed by qPCR (A) and lung edema level was evaluated by the gravimetric 
method and expressed as lung wet-to-dry ratio (B). Data are expressed as mean ± SEM (n=5-8, per 
group). 
 
 
4.11. Trichostation A does not decrease alveolar-capillary 
barrier permeability in bleomycin-treated mice  
The impact of the TSA on alveolar-capillary barrier function in the bleomycin 
ARDS model was assessed by measurement of the total protein concentration in the 
BAL fluid and by Evans blue extravasation assay. As depicted in Figure 19A and 19B, 
bleomycin instillation induced the accumulation of protein in the BAL fluid and 
increased permeability of the endothelial barrier to Evans blue dye. However, TSA 
treatment did not decrease total protein levels in BAL fluid and did not reduce the Evans 
blue index. These data indicate that TSA does not affect permeability of the  
alveolar-capillary barrier in the bleomycin model of ARDS. 
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Figure 19. Effect of trichostatin A on alveolar-capillary barrier permeability in the bleomycin 
model of acute respiratory distress syndrome. C57BL/6J mice were instilled with bleomycin to initiate 
lung injury. At 24 h later, mice received intraperitoneal injection of trichostatin A (TSA) or vehicle for 
four subsequent days. The alveolar-capillary barrier permeability was analyzed by measurement of the 
total protein concentration in the broncho-alveolar lavage fluid (A) and Evans blue extravasation assay 
(B). Data are expressed as mean ± SEM (n=3-5, per group). 
 
 
4.12. The inflammatory response is not modified by histone 
deacetylase inhibition in the bleomycin model of acute 
respiratory distress syndrome 
Alveolar macrophages, neutrophils and lymphocytes mediate the inflammatory 
response in ARDS. The differential analysis of the inflammatory cells in BAL fluid 
revealed that bleomycin instillation decrease the number of alveolar macrophages and 
promoted neutrophil and lymphocyte recruitment to the lung in bleomycin model of 
ARDS (Figure 20). However, the treatment with TSA did not increase the percentage of 
alveolar macrophages (Figure 20A) and did not reverse neutrophil and lymphocyte 
sequestration to the alveoli after bleomycin instillation (Figure 20B and 20C). These 
data indicate that histone deacetylases do not mediate inflammatory responses in the 
bleomycin model of ARDS. 
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Figure 20. The effect of trichostatin A on inflammatory responses in the bleomycin model of acute 
respiratory distress syndrome. C57BL/6J mice were instilled with bleomycin to initiate lung injury.  
24 h later, mice received an intraperitoneal injection of trichostatin A (TSA) or vehicle for four 
subsequent days. After animals were sacrificed, the BAL fluid was collected and cells were recovered by 
cytospin centrifugation. Mean % of alveolar macrophages (A), neutrophils (B) and lymphocytes (C) in 
BAL fluid was identified by differential staining. Data are expressed as mean ± SEM (n=5, per group). 
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5. Discussion  
The current concept of the pathological mechanisms at play in ARDS highlight the 
causative role of deregulated Na
+
 transporting machinery which negatively impacts AFC 
and, therefore, promotes the persistence of pulmonary edema (Sartori and Matthay, 
2002). The TGF-β is widely recognized as a critical mediator of ARDS pathogenesis, 
and the involvement of the TGF-β pathway in disruption of Na+ transport and 
pulmonary edema formation has been established (Wesselkamper et al., 2005, Budinger 
et al., 2005, Fahy et al., 2003, Pittet et al., 2001). In this study, the question has been 
asked whether the expression of Na,K-ATPase subunit-encoding genes are differentially 
regulated in ARDS and if whether TGF-β can modulate expression of Na,K-ATPase 
subunits-encoding genes.  
The comparison of in vivo and in vitro expression patterns revealed that FXYD1 
and ATP1B1 genes were similarly regulated in lung tissues from patients with ARDS, 
and in TGF-β-treated A549 cells. The expression of the FXYD1 gene was significantly 
upregulated in lungs from ARDS patients and in TGF-β-stimulated cells, when 
compared to control samples. The auxiliary subunit FXYD1 regulates Na,K-ATPase 
function in a tissue-specific context. The FXYD1 protein has been shown to decrease 
the apparent Na
+
 and K
+
 affinity of Na,K-ATPase (Geering, 2006). Moreover,  
FXYD1-deficient mice exhibit increased Na,K-ATPase activity in cardiomyocytes which 
suggests that the upregulated FXYD1 gene expression observed in ARDS might 
contribute to decreased Na
+
 transport across the alveolar epithelium (Geering, 2008). 
The ATP1B subunit is a critical component of the Na,K-ATPase complex and 
ATP1B1 is the most abundantly expressed isoform in the lung (Flodby et al., 2012). In 
the present study, expression of the ATP1B1 gene was demonstrated to be reduced in the 
lungs from ARDS patients and in TGF-β-treated A549 cells when compared to healthy 
lungs and untreated cells, respectively. A parallel trend was observed in the bleomycin 
model of ARDS and in primary mouse AETII cells treated with TGF-β. Furthermore, 
downregulation of Atp1b1 gene expression has been also reported in a nickel model of 
ARDS (Wesselkamper et al., 2005). These data indicate that repression of the ATP1B1 
gene expression is a common reaction of the lung epithelium to injury.  
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5.1. The expression of the ATP1B1 gene is strictly regulated 
by TGF-β 
The main focus of this study was to understand the mechanism of ATP1B1 gene 
repression by the TGF-β pathway. Doses of TGF-β employed in the present study (up to 
10 ng/ml) were chosen to simulate pathological situation of ARDS where TGF-β was 
reported at a concentration of 7-14 ng/ml in BAL fluid (Budinger et al., 2005, Dhainaut 
et al., 2003, Fahy et al., 2003). The recognition of the ligand by the membrane-bound 
receptors marks the initiation of TGF-β signaling and immediately leads to activation of 
the secondary messengers, the SMAD transcription factors (Massagué and Gomis, 
2006). In the present study, inhibition of the TBRI receptor by SB431542 prevented 
SMAD2 and SMAD3 phosphorylation, and abolished downregulation of the ATP1B1 
gene. Furthermore, specific knock-down of SMAD2 and a common partner SMAD4, 
but not SMAD3, rescued ATP1B1 gene expression. Together, these results demonstrate 
a central role of SMAD transcription factors in ATP1B1 gene regulation and indicate 
that a complex consisting of SMAD2/SMAD4 rather than SMAD3/SMAD4 mediates  
TGF-β-controlled repression of the ATP1B1 gene.  
Apart from SMADs, TGF-β signaling utilizes a variety of other transcription 
factors to control the gene expression. The siRNA-mediated knock-down of SNAI1 and 
E2F5, but not of YY1, RUNX2, SNON and E2F4, prevented downregulation of 
ATP1B1 gene expression in response to TGF-β. Chen and colleagues investigated in the 
detail the interaction between SMAD2, SMAD3 and E2F5 and reported a critical role of 
a complex consisting of these proteins in the repression of the c-myc gene by TGF-β 
(Chen et al., 2002). Analysis of the ATP1B1 promoter sequence in the present study 
revealed the presence of a region located at -2118 to -2110 bp upstream from 
transcription start site, which was highly similar to the E2F5 binding element 
characterized in the c-myc gene. The association of SNAI1 with SMAD3 and SMAD4 
has been reported to play a critical role in repression of CAR, OCCLUDIN, CLAUDIN-3 
and E-CADHERIN genes in TGF-β-driven epithelial-to-mesenchymal transition 
(Vincent et al., 2009). More importantly, SNAI1 has been demonstrated to bind the 
noncanonical E-box element located in the -71 to -66 bp region upstream from the 
transcriptional start site of the ATP1B1 gene, and repress this gene expression in  
poorly differentiated carcinoma cell lines (Espineda et al., 2004). However, the  
TGF-β-responsive ATP1B1 promoter region (-3075 to -1238 bp) cloned for the purpose 
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of this study, lacked a noncanonical E-box element located within the -71 to -66 bp 
region upstream from the transcriptional start site. A bioinformatic analysis of the 
cloned ATP1B1 promoter sequence identified another noncanonical E-box element, 
located in the region -1562 to -1557 bp upstream of the transcriptional start site. Since 
SNAI1 has been shown here to mediate TGF-β-induced repression of the ATP1B1 gene, 
one can speculate that the noncanonical E-box element located within the -1562  
to -1557 bp region upstream of the transcriptional start site might be alternative site 
recognized by SNAI1. Collectively, evidence presented here and in previously published 
studies indicate that SMAD2, SMAD4, SNAI1 and E2F5 are involved in ATP1B1 gene 
repression by TGF-β.  
 
5.2. TGF-β signaling employs epigenetic machinery to 
regulate the ATP1B1 gene 
In addition to recruitment of DNA-binding transcription factors, TGF-β signaling 
employs epigenetic machinery to regulate the expression of target genes (Feng and 
Derynck, 2005). Here, the involvement of DNA methylation in the regulation of the 
ATP1B1 gene by TGF-β was investigated. The inhibition of DNA methylation by  
5-Aza-2′-dC resulted in the loss of the ability of TGF-β to modulate ATP1B1 gene 
transcription and promoter activity. These data suggest that TGF-β may regulate the 
ATP1B1 gene by altering the DNA methylation pattern. Interestingly, the use of 10 μM  
5-Aza-2′-dC reduced ATP1B1 gene transcription and promoter activity in both  
TGF-β-treated as well as in control cells to the same level as in cells stimulated with 
TGF-β only. This observation may indicate that DNA methylation in the ATP1B1 gene 
promoter is important for normal expression of this gene under normal conditions. 
Additionally, Thillainadesan and colleagues recently reported that TGF-β signaling 
recruits the DNA-demethylating machinery which has a functional impact on p15
ink4b
 
gene expression (Thillainadesan et al., 2012). Therefore, it may be possible that TGF-β 
employs a DNA-demethylating complex to actively demethylate the ATP1B1 promoter 
and repress the ATP1B1 gene expression.   
Regulation of histone acetylation is another epigenetic mechanism which can 
serve to modulate the gene expression (Wu and Grunstein, 2000). Several TGF-β 
associated transcription factors have been shown to recruit HDACs and to form 
functional complexes in order to repress target genes (Massagué et al., 2005). Treatment 
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with the pan-HDAC inhibitor TSA released the ATP1B1 gene from TGF-β-mediated 
repression in A549 cells and in primary mouse AETII cells, clearly indicating that  
TGF-β downregulates ATP1B1 gene by utilizing HDACs. Furthermore, the use of  
class-specific HDAC inhibitors revealed that class I but not class II HDACs are involved 
in the downregulation of the ATP1B1 gene expression and promoter activity by TGF-β. 
Further investigations elucidated a specific role for the class I HDAC member, HDAC2, 
in the ATP1B1 gene repression. As HDAC2 has been detected in the alveolar 
epithelium, the TGF-β/HDAC2 axis could perhaps facilitate repression of the ATP1B1 
gene in vivo (Yin et al., 2006). Additionally, the importance of HDAC2 in the context of 
lung disease has already been stressed in pathogenesis of COPD (Barnes, 2009). The 
mechanism of HDAC-dependent gene repression involves the deacetylation of the 
histone proteins associated with the gene promoter region. The activity of the ATP1B1 
promoter was preserved in cells co-treated with TSA and TGF-β, implying that the 
repressive histone deacetylation occurs within the -3075 to -1238 bp region upstream 
from the transcriptional start site. Results of the ChIP experiments demonstrated that 
HDAC2 interacts with the region located between -1339 to -1241 bp upstream from the 
transcriptional start site of the ATP1B1 gene. While the apparent HDAC2 abundance on 
the promoter was not increased after TGF-β treatment, TGF-β induced HDAC2 
phosphorylation at serine 394. The HDAC2 has been found to be regulated by 
phosphorylation at serine 394 which potentates enzymatic activity and is an essential 
step during the formation of repressor complexes (Tsai and Seto, 2002). These results 
indicate that TGF-β executes ATP1B1 gene repression by inducing HDAC2 activity 
rather than promoting sequestration of additional HDAC2 molecules to the promoter 
region.  
In the present study, SMAD2, SMAD4, E2F5, SNAI1 and HDAC2 were 
reported to mediate repression of the ATP1B1 gene in response to TGF-β. While direct 
interaction between HDAC2 and SMAD2, SMAD4 or E2F5 has not previously been 
reported, SNAI1 has been demonstrated to directly interact with HDAC2 on the  
E-CADHERIN promoter (Peinado et al., 2004). As mentioned above, SNAI1 was 
reported to repress the ATP1B1 gene, and the TGF-β-induced interaction between 
SNAI1 and SMADs has been documented (Vincent et al., 2009, Espineda et al., 2004). 
Based on this evidence, it is reasonable to hypothesize that SMAD2, SMAD4 and 
SNAI1 together with HDAC2 mediate the repression of the ATP1B1 gene expression by 
the TGF-β. 
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5.3. The inhibition of histone deacetylases rescues Atp1b1 
gene expression and reduces pulmonary edema 
The availability of the ATP1B subunits is a rate limiting factor for Na,K-ATPase 
assembly and activity, since ATP1A subunits alone are unable to integrate into the cell 
membrane (Geering, 2008, Barquin et al., 1997). Taking into account the fundamental 
role of ATP1B1 in the regulation of Na,K-ATPase, one can hypothesize that 
downregulation of ATP1B1 gene expression in ARDS, and in the bleomycin model of 
this disease reported here, may prevent resolution of pulmonary edema by impairing Na
+
 
transport and AFC. The importance of the Atp1b1 gene in the regulation of the lung 
water homeostasis has been confirmed in Atp1b1 gene knock-out mice, which displayed 
a major reduction in the AFC (Flodby et al., 2012). Additionally, experiments on 
primary mouse alveolar epithelial cell monolayers lacking the Atp1b1 gene 
demonstrated decreased transepithelial Na
+
 conductance (Kim et al., 2011). 
In vitro experiments presented in this study provide strong evidence for a key role 
for the HDAC2 in ATP1B1 gene repression by TGF-β. Therefore, the possibility that 
HDAC inhibition would prevent Atp1b1 gene repression in bleomycin-instilled mice has 
been tested. Treatment with TSA reversed downregulation of Atp1b1 gene expression in 
the bleomycin model of ARDS. In parallel, animals co-treated with bleomycin and TSA 
displayed decreased lung wet-to-dry mass ratio. This observation signifies the presence 
of an inverse relationship between levels of Atp1b1 gene expression, and levels of 
pulmonary edema, and indicates a beneficial effect of increased Atp1b1 gene expression 
on AFC. Furthermore, the augmented expression of the Atp1b1 gene by gene transfer 
has already been shown to significantly boost the Na
+
 transport, AFC clearance and 
improve pulmonary edema (Adir et al., 2003, Azzam et al., 2002, Stern et al., 2000, 
Factor et al., 2000, Factor et al., 1998).  
Collectively, these data indicate that reduced Atp1b1 gene expression may be 
involved in water persistence in lungs of bleomycin-instilled mice and restored 
expression of the Atp1b1 gene by TSA could augment Na,K-ATPase activity and AFC 
resulting in decreased edema. Moreover, the use of an HDAC inhibitor provided an 
alternative method to gene transfer to reactivate Atp1b1 gene expression in order to 
reduce pulmonary edema. To date, HDAC inhibitors have been approved for the 
treatment of cutaneous T-cell lymphoma, and peripheral T-cell lymphoma and more 
than 80 clinical trials are currently evaluating the efficacy of over 11 different HDAC 
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inhibitors for the treatment of various malignancies (Ververis et al., 2013). Given the 
fact that only minor side effects were observed in these studies, it could be speculated 
that HDAC inhibitors could prove to be a valid pharmacological option for the treatment 
of ARDS.  
In addition to the fundamental role in Na
+
 transport and AFC, the novel function 
of the ATP1B1 subunit in the maintenance of tight epithelial layers has been recently 
proposed (Vagin et al., 2012). Therefore, a reduction in the level of pulmonary edema 
by TSA could be achieved by increased AFC and/or reduced alveolar-capillary barrier 
permeability. However, since TSA treatment neither reduced protein content in the BAL 
fluid nor decreased albumin extravasation, it can be interpreted that HDAC inhibition 
does not improve alveolar-capillary barrier integrity but stimulates Na
+
 transport and 
effective AFC. This conclusion is supported by observations that ATP1B1 gene transfer 
does not reduce alveolar permeability to albumin in a rat model of acute hydrostatic 
pulmonary edema, regardless of restored Na
+
 transport and AFC (Azzam et al., 2002).   
Despite that TSA decreased pulmonary edema, it cannot be excluded that 
mechanisms other than an Atp1b1-dependent increase in ion transport could restore lung 
water homeostasis. The possibility that TSA could improve lung water by reducing lung 
inflammation in the bleomycin model of ARDS was explored by characterization of the 
inflammatory cell profile in the alveolar space. Here, bleomycin instillation clearly 
provoked an inflammatory response in alveoli by increasing the fraction of the 
neutrophils and leukocytes, while decreasing the amount of alveolar macrophages. This 
dramatic change in the inflammatory cell profile by bleomycin remained unaffected by 
TSA treatment, implying that HDAC-mediated gene regulation does not alter the 
migration of inflammatory cells across the epithelial barrier. This finding is contrary to 
previously published results on HDAC inhibition effects in cecal ligation and  
puncture-induced polymicrobial sepsis and lipopolysaccharide model of ARDS. In these 
mice pre-treated with TSA or sodium butyrate HDAC inhibitors, neutrophil infiltration 
was reduced (Ni et al., 2010, Zhang et al., 2010). This discrepancy could be explained 
by the fact that Ni et al. and Zhang et al. used HDAC inhibitors as a preventive strategy 
before induction of lung injury, while in the present study, TSA was used 24 h after 
bleomycin instillation. Therefore, one could speculate that HDAC inhibition employed 
as a therapeutic approach has a limited effect on modulation of the inflammatory 
response. Finally, since HDAC inhibition neither altered inflammatory responses nor 
decreased protein levels in BAL fluid, improvement of pulmonary edema by TSA in the 
Discussion 
 70 
bleomycin model of ARDS could be attributed to the increased AFC. The proposed 
mechanism of ATP1B1 gene repression by the TGF-β/HDAC2 axis in the context of 
AFC and ARDS has been summarized in Figure 21.  
 
 
 
Figure 21. Model of TGF-β/HDAC2-regulated ATP1B1 gene repression, decreased Na+ transport 
and impaired alveolar fluid clearance in acute respiratory distress syndrome. Lung water balance is 
achieved by transepithelial Na
+
 transport mediated by ENaC and Na,K-ATPase. In acute respiratory 
distress syndrome, activation of TGF-β signaling causes repression of the ATP1B1 gene which is critically 
mediated by the epigenetic co-repressor HDAC2. Downregulation of the ATP1B1  
subunit-encoding gene expression results in the decreased abundance of the Na,K-ATPase on the 
basolateral cell membrane and blocked Na
+
 transport. Consequently, reduced Na
+
 transport impairs 
alveolar fluid clearance (AFC) and promotes persistence of pulmonary edema. The inhibition of histone 
deacetylases by trichostatin A (TSA) rescues the ATP1B1 gene expression and allows the reinsertion of 
the Na,K-ATPase into cell membrane. This reactivates Na
+
 transport and potentates AFC which ultimately 
reduces pulmonary edema. 
 
In summary, data presented here advocate a key role for the TGF-β/HDAC2 axis 
in repression of the ATP1B1 gene in the alveolar epithelium in ARDS. TGF-β, a potent 
mediator of ARDS, activates HDAC2 which represses the ATP1B1 gene by direct 
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interaction with the promoter region. This HDAC2-mediated repression mechanism was 
sensitive to inhibition of histone deacetylation, which resulted in induction of ATP1B1 
gene expression. Finally, HDAC inhibition also abrogated repression of the Atp1b1 gene 
in bleomycin model of ARDS and decreased lung water content in parallel. As the 
Atp1b1 gene performs essential role in efficient Na
+
 transport and AFC, it is tempting to 
conclude that HDAC inhibition and subsequent increase in the Atp1b1 gene expression 
reduced pulmonary edema in bleomycin model of ARDS. Ultimately, data collected in 
the present study indicate that inhibition of HDACs in ARDS could be a viable 
therapeutic option to improve pulmonary edema in this currently incurable disorder. 
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V. Summary 
Acute respiratory distress syndrome (ARDS) is a devastating disease 
characterized by high mortality with no available pharmacological therapy. 
Transforming growth factor (TGF)-β mediates ARDS by promoting formation and 
persistence of alveolar edema. The deregulation of the Na,K-ATPase, a key Na
+
 
transporter in the alveolar epithelium, has been reported in ARDS, where impaired 
Na,K-ATPase function perturbs alveolar fluid clearance (AFC). In the present study, 
downregulation of ATP1B1, a gene encoding an essential subunit of the  
Na,K-ATPase, has been observed in ARDS patients, bleomycin model of ARDS and in 
TGF-β-treated primary mouse alveolar epithelial type II cells and A549 cells. A 
mechanism of TGF-β-regulated repression of the ATP1B1 gene relied on SMAD2, 
SMAD4, SNAI1 and E2F5 transcription factors. Moreover, epigenetic machinery 
involving DNA methylation and action of histone deacetylases (HDAC) have been 
found to mediate the TGF-β-controlled downregulation of the ATP1B1 gene. The class I 
HDAC member, HDAC2, has been identified as a critical element involved in ATP1B1 
gene repression, and has been observed to bind the ATP1B1 promoter and to be 
activated by TGF-β signaling. The treatment with the histone deacetylase inhibitor 
trichostatin A (TSA) rescued expression of the Atp1b1 gene in the bleomycin model of 
ARDS which was accompanied by decreased lung wet-to-dry ratio. However, TSA 
neither decreased alveolar-capillary barrier permeability nor alleviated inflammatory 
responses indicating that reduction of edema was attributable to restored Na
+
 transport 
and increased AFC.  
These data describe a novel system of HDAC-regulated repression of the Atp1b1 
gene by TGF-β which could be targeted and disrupted by HDAC inhibition in the 
bleomycin model of ARDS. Therefore, this study provides strong evidence to support 
the use of HDAC inhibitors in pharmacological therapy of ARDS. 
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VI. Zusammenfassung 
Das akute Atemnotsyndrom (engl. acute respiratory distress syndrome, ARDS) 
ist eine verheerende Krankheit, die mit einer hohen Sterblichkeit verbunden ist und für 
die es keine pharmakologische Therapie gibt. Der transformierende Wachstumsfaktor 
(engl. transforming growth factor (TGF))-β fördert in ARDS die Formierung sowie den 
Erhalt des Alveolarödems. Wissenschaftliche Arbeiten zeigen auf, dass die  
Na,K-ATPase, eine der wichtigsten Na
+
 Transporter im Alveolarepithel, in ARDS 
dereguliert ist und das eine gestörte Funktion der Na,K-ATPase zu einer verringerten 
alveolären Flüssigkeitsklärung (engl. alveolar fluid clearance, AFC) führt. In der 
vorliegenden Studie konnte festgestellt werden, dass es zu einer Herunterregulierung 
von ATP1B1, dem Gen, das die essentielle Untereinheit der Na,K-ATPase codiert, in 
Patienten mit ARDS, im Bleomycin Modell von ARDS, in TGF-β behandelten primären 
alveolaren Epithelzellen von Typ II der Maus und in A549 Zellen, kam. Der 
Mechanismus durch den TGF-β die Repression des  ATP1B1 Gens regulierte, beruhte 
auf den Transkriptionsfaktoren SMAD2, SMAD4, SNAI1 und E2F5. Des Weiteren 
konnte festgestellt werden, dass epigenetische Mechanismen, einschließlich DNA 
Methylierung sowie Einwirkungen der Histondeacetylasen (HDAC) an der TGF-β 
kontrollierten Herrunteregulierung von ATP1B1 beteiligt sind. Das Klasse I HDAC 
Mitglied HDAC2, wurde als Schlüsselelement in der  ATP1B1 Genreprimierung 
identifiziert und es konnte gezeigt werden, dass HDAC2 den Promotor von ATP1B1 
binden und durch TGF-β aktiviert werden kann. Die Behandlung mit dem 
Histondeacetylaseninhibitor Trichostatin A (TSA) führte zu einer „Rettung“ der Atp1b1 
Genexpression im Bleomycin Modell von ARDS und war mit einem reduzierten  
Nass-Trocken-Verhältnis der Lunge verbunden. Dabei führte TSA jedoch weder zu 
einer Reduzierung der alveolarkapillären Permeabilität noch kam es zu einer Linderung 
der Entzündungsreaktion, was darauf hinwies, dass das reduzierte Ödem auf die 
Wiederherstellung Na
+
 Transports und auf eine Erhöhung des AFC zurückzuführen war. 
Diese Daten beschreiben ein neues System einer HDAC-regulierten 
Reprimierung des Atp1b1 Gens durch TGF-β, welches durch eine HDAC Inhibierung im 
Bleomycin Modell von ARDS gezielt angegriffen und umgekehrt werden kann. Daher 
liefert diese Studie einen starken Beweis der einen Einsatz von HDAC Inhibitoren in der 
pharmakologischen Therapie von ARDS rechtfertigen würde. 
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